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COFACTOR CONTROL OF A VITAL ENZYMATIC REACTION: THE
EFFECT OF FACTOR VA ON THROMBIN FORMATION DURING BLOOD
COAGULATION

JAMILA HIRBAWI

ABSTRACT
The LONG-TERM goal of our research is to study and analyze the structure and
function of the factor V molecule in order to understand its regulatory effects on the
natural process of hemostasis and its role in the life-threatening development of deep
venous thrombosis.
The SHORT-TERM goal of our research is to identify the amino acid residue(s) of
factor V that interact with prothrombin during the assembly and function of the
prothrombinase complex in order to fully understand its particular role in maintaining the
integrity of the blood coagulation cascade. The final goal of the coagulation cascade is
the formation of a fibrin clot that is catalyzed by the serine protease, thrombin. The
proteolytic conversion of prothrombin to thrombin is catalyzed by the prothrombinase
complex composed of the enzyme, factor Xa, its cofactor, factor Va, assembled on a
membrane surface in the presence of divalent metal ions. Although factor Xa alone can
activate prothrombin, it is at a rate that is not compatible for survival. Incorporation of
factor Va into the prothrombinase complex results in a 300,000-fold increase in the
catalytic efficiency of factor Xa for thrombin generation and plays an important role in
v

regulating prothrombin activation. Thus, it is crucial to identify which specific amino
acid residue(s) are responsible for the interaction of factor Va with prothombin and factor
Xa in the formation of thrombin, which is absolutely vital for maintaining normal
hemostasis in a healthy individual.
The specific aims of the present study are; To identify the specific amino acid
region of the factor Va heavy chain that promotes optimal cofactor function during
prothrombin activation; To identify key acidic amino acid sequences in the factor Va
molecule that control the rate of prothrombin cleavage; To identify the specific amino
acids of the factor V/Va heavy chain that regulate enzyme-substrate interaction during
prothrombin activation.
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CHAPTER I
INTRODUCTION

An estimated eighty million Americans have one or more forms of cardiovascular
disease. Among these numbers are individuals who suffer from high blood pressure,
coronary heart disease, and ischemic stroke.

An important factor involved in the

evolution of these disorders, is the process of hemostasis. Hemostasis is the body’s
natural mechanism for the control of excessive bleeding after injury, as well as
prevention of a hypercoagulative state during the coagulation response. This procedure
involves a series of enzymatic reactions that are all tightly regulated in order for proper
clot formation to occur at the sight of injury [1, 2]. Without proper control, a range of
thrombotic and hemorrhagic difficulties can arise. These tendencies can be attributed to
genetic disorders or can be acquired through various outside factors.
Thrombosis is the formation of a blood clot within the vasculature such as an
artery or a vein that causes the blockage of blood flow through the circulatory system.
There are two forms of veins present in an individual’s legs. Superficial veins are located
just beneath the surface of the skin, while deep veins are found deep within the muscles
of the leg.
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Deep venous thrombosis (DVT) is a condition where an unwanted blood clot forms in the
thigh or lower leg [3]. This pathological state can progress to a more fatal stage once a
small portion of the clot (embolus) is dislodged, circulates in the system through the heart
and remains lodged in the lung. A pulmonary embolism will cause blood supply to the
lung to be blocked therefore, depleting it of oxygen and carbon dioxide exchange and
ultimately causing necrosis of the lung tissue followed by death.
In contrast, hemophilia is an inherited disorder that involves prolonged bleeding
after injury [4]. There are two major forms of the disease caused by an x-linked recessive
trait. Hemophilia A is caused by a deficiency in the clotting factor, factor VIII and
hemophilia B is due to a deficiency in factor IX [5]. Individuals affected with these
deficiencies usually suffer bleeding episodes that range from mild to severe. In addition,
acquired hemophilia is an autoimmune disorder, in which a person with normal
haemostatic activity spontaneously develops autoantibodies against the blood clotting
factors, more frequently factor VIII. This condition generally occurs as a result of
various medical issues such as pregnancy, autoimmune disorders, diabetes, respiratory
disease, and a variety of malignancies.
Another frequently seen clotting disorder involves the inability of the coagulation
response to halt in a timely manner. APC (activated protein C) is the enzyme responsible
for the inactivation of the clotting factors, FVa and FVIIIa, when bound to its cofactor,
protein S [6] . Factors Va and VIIIa are important facilitators in the formation of a blood
clot. APC resistance occurs in about 25-40% of patients with a family history of
thrombotic conditions and in about 3-5% of the normal population [7]. Deficiency in
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either protein C or protein S will cause the continued accumulation of thrombus
formation due to inadequate quantities present to inactivate FVa and FVIIIa.
1.1 Hemostasis
Primary hemostasis is the body’s initial response to injury to the endothelial
surface of a blood vessel. This initial phase is characterized by constriction of the blood
vessel, blood platelet adhesion to the surface, and the formation of a “soft plug” [8].
Once damage occurs, vasoconstriction limits the flow of blood to the damaged area.
Platelets then become activated by thrombin and soon aggregate at the site of injury. Cell
adhesion occurs when glycoproteins present on the platelet surface bind to von
Willebrand (vWD) factor that attaches to the endothelim.

Platelets then clump by

binding to collagen that is exposed during initial rupture of the blood vessel lining.
Individuals, who have decreased amounts of circulating vWD factor, suffer from
bleeding of the skin and mucous membranes due to interruption of primary hemostais. In
addition, vWD factor also binds and stabilizes circulating factor VIII, which is involved
in the intrinsic pathway of secondary hemostasis.

There are three types of von

Willebrand disease, with type III being the most severe and rare form. Although the
initial plug arrests bleeding, it must be stabilized through secondary hemostasis. This
process involves a series of reactions induced by coagulation factors that serve as
enzymes and coenzymes, the presence of calcium, and a phospholipid surface that is
usually presented by the activated platelets [9]. Defects in this system may lead to serious
bleeding disorders including internal bleeding of the cavities and subcutaneous
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hematomas.

In addition, deficiencies in circulating blood factors and/or genetic

mutations can incur risk of thrombotic episodes.
1.2 The Coagulation Cascade
The coagulation response is of utmost importance in the maintenance of normal
hemostasis in healthy individuals. Any slight disruption of this mechanism can lead to
abnormalities that eventually cause heart disease, stroke, or blood pressure variations.
The penultimate goal of the coagulation cascade is the generation of thrombin, which in
turn converts fibrinogen to fibrin to generate a fibrin plug. Thrombin generation is
divided into three separate segments: the initiation phase where low levels of α-thrombin
are produced; the propagation phase when a considerable amount of thrombin is created
and the fibrin plug is formed; and the termination phase where the inhibition of thrombin
and many of the serine proteases involved in the coagulation cascade takes place due to
the inhibitors TFPI (tissue factor pathway inhibitor) and AT-III (antithrombin III); and
inactivation of the cofactors (fVa and fVIIIa) by activated Protein C (APC)/Protein S
[10]. This response is initiated by cellular and vascular injury and can be initially divided
into two distinct pathways, followed by the common pathway [11] (Fig.1.1).
The extrinsic pathway (tissue factor pathway) is initiated with the exposure of
tissue factor (TF) after vascular damage. Tissue factor is a cell surface glycoprotein that
serves as a cofactor for factor VIIa [12, 13]. TF will bind to factor VIIa to form the
extrinsic tenase complex that will activate factor X [14]. In addition, factor VII can also
be activated by factor Xa and thrombin. Activated factor X (fXa) will then go on to the
common pathway where the prothrombinase complex is formed with its cofactor, factor

4

Fig. 1.1: The Blood Coagulation Pathway. The blood coagulation cascade includes the
extrinsic and extrinsic pathways, which combine at the common pathway where the
prothrombinase complex forms to continue prothrombin activation. This process will
eventually lead to the formation of the fibrin plug after vascular injury. (from
www.kingsnake.com)

5

Va, on a membrane surface in the presence of Ca2+ to activate the substrate, prothrombin.
Consequently, the TF-FVII complex will also activate factor IX that will play a role in
the intrinsic pathway [15]. The extrinsic pathway is rapidly inhibited by tissue factor
pathway inhibitor (TFPI), a serine protease inhibitor that is associated to lipoprotein
molecules. Although this pathway is inhibited quickly, sufficient quantities of thrombin
are formed to activate factor XI [12]. Factor XIa will participate in the intrinsic pathway,
inducing the amplification of the coagulation response.
The intrinsic pathway, involves the conversion of factor XI to XIa by factor XIIa.
Activated factor XII is a key component in the generation of bradykinin and
implementation of fibrinolysis and is the initial activator of the intrinsic pathway. Factor
XIa will convert factor IX to factor IXa. This enzyme will associate on a membrane
surface with its cofactor, factor VIIIa in the presence of calcium to form the intrinsic
tenase complex [16]. Intrinsic tenase will activate factor X that will be incorporated into
prothrombinase for thrombin generation. The intrinsic pathway is not important for
initiation of the coagulation cascade. However, it is responsible for amplification of the
process due to production of large amounts of factor Xa and thrombin.
Once enough factor Xa is generated through the extrinsic and intrinsic pathways,
the common pathway takes part in the generation of human alpha thrombin through
conversion of prothrombin by the prothrombinase complex. This complex is composed
of the enzyme, factor Xa, with its non-enzymatic cofactor, factor Va, on a phospholipid
surface, (provided by the activated platelets), in the presence of Calcium ions [17].
Although factor Xa can activate prothrombin with an initial cleavage at Arg271 followed
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by cleavage at Arg320 to yield the intermediates Fragment 1.2 and Prethrombin 2,
incorporation of factor Va into the prothrombinase complex results in a reversal of
cleavages and a 300,000-fold increase in the catalytic efficiency of factor Xa for
thrombin generation [18]. Thrombin will proceed to convert fibrinogen to fibrin to
produce a stable clot.
1.3 Blood Coagulation Factor V
Coagulation factor V circulates in plasma at a concentration of 20 nM, as a single
chain protein of Mr 330,000 consisting of three protein domains (A, B, & C) that are
arranged in the order of A1-A2-B-A3-C1-C2 [1] (Fig. 1.2). In addition, factor V can be
found in a partially active state in the α-granules of platelets. It is cleaved by α-thrombin
(fIIa) at Arg709, Arg1018, and Arg 1545 to release the B domain (containing a large number
of asparagines-linked oligosaccharides) and generate an active cofactor (fVaIia) composed
of a light chain of Mr 74 kDa (A3-C1-C2 domains) and a heavy chain of Mr 105 kDa
(A1-A2 domains) that is involved in prothrombinase complex formation and function
[19, 20]. The amino-terminal heavy chain (amino acids 1-709) is associated via Ca2+ ions
to the carboxy-terminal light chain (amino acids 1546-2196). The B domain has been
shown to have sequences recognized by α-thrombin for activation of the cofactor [21].
While thrombin is a major activator of the human factor V molecule, it also has been
implicated in the inactivation of the cofactor. In previous studies, it was determined that
cleavage at Arg643 of the COOH-terminal region of the heavy chain resulted in a partially
inactive molecule [22]. In addition to thrombin, various proteases can cleave factor V to
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Fig. 1.2: Human Factor V. Schematic of the factor V molecule with various
modifications and activation/deactivation sites.

8

induce activation. The procofactor can be activated by Russell’s viper venom (RVV-V)
through cleavage at Arg1018 and Arg1045, resulting in a cofactor with approximately the
same activity as factor VaIIa. Proteolytic cleavage of the procofactor can also be induced
by the serine proteases found in polymorphonuclear leukocytes (PMN), Cathepsin G and
Human Neutrophil Elastase (HNE). These enzymes give result to a cofactor with a
truncated heavy chain missing vital amino acid residues necessary for interaction with
prothrombin during thrombin formation. Cathepsin G will cleave factor V at Phe1031,
Leu1447, Tyr1518, and Tyr696 to yield a 103 kDa heavy chain and 80 kDa light chain.
Elastase will activate factor V through cleavage at Ile708, Ile819, Ile1484, and Thr678 to
produce a 102 kDa heavy chain and 90 kDa light chain. Other proteases involved in
factor V cleavage include the protease from the venom of the snake naja naja oxiana,
factor Xa, and the prothrombin activation intermediate, meizothrombin [18].
1.4 Factor Va Inactivation
Factor Va can be inactivated by the anticoagulant, activated protein C (APC).
Protein C is a 62,000 Mr protein that circulates in plasma at a concentration of 60 nM. It
consists of a heavy chain and light chain, which are held together by a single disulfide
bridge[23] . When cleaved at Arg169 of the heavy chain by the thrombin-thrombomodulin
complex, protein C is converted to the active enzyme, APC. APC cleaves factor Va
sequentially at Arg506, Arg306, and Arg679 in the presence of its cofactor protein S to yield
an inactive factor Va molecule that can no longer bind to factor Xa or prothrombin [24].
Cleavages at Arg506 and Arg306 occur with the involvement of a phospholipid surface
with the latter being strictly dependent on the presence of a membrane surface [25].
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Initial cleavage occurs at Arg506 to yield a factor Va molecule that is partially active and
has a lower affinity for the enzyme, factor Xa. Once cleavage at Arg306 takes place, total
deactivation of the cofactor is obtained [26]. In addition to APC inactivation, factor Va
can also be cleaved at Arg643 by human alpha thrombin in the presence of endothelial
cells to yield an inactive product [22]. Factor Va will also be inactivated by plasmin
which will cleave at Lys309, Lys310, Arg313, and Arg348 in the presence of a membrane
surface and cause the A2 domain to dissociate from the rest of the molecule [27].
1.5 Factor Va interaction with factor Xa.
Appropriate binding of factor Va to factor Xa during prothrombinase function is
crucial to the proper activation of the substrate, prothrombin. Factor Va increases the
catalytic efficiency of factor Xa for prothrombin activation by a great magnitude. It has
been shown that factor Va increases the kcat and decreases the Km of the reaction along
with inducing sequential cleavages at Arg320 and Arg271 to induce the meizothrombin
pathway in the presence of phospholipids [28]. The increase in Kcat value is attributed to
cofactor interaction with the enzyme, while the decrease in Km is due to the γcarboxyglutamic acid-dependent (Gla domain) interaction of factor Xa and prothrombin
with the phospholipid suface . Factor Va binds to both the light and heavy chains of
factor Xa including amino acids 211-222 and 254-274 of the catalytic domain of factor
Xa [29, 30]. Cofactor binding to factor Xa has also been found to expose cryptic exosites
on fXa that are recognition sites for its substrate, prothrombin [31].

Previous data has

indicated that amino acids located on various portions of the heavy chain have had
enormous effects on prothrombinase formation and function. A nonapeptide (AP4’) with
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amino acid sequence Glu323-Val331 of the factor Va A2 domain of the heavy chain was
found to have inhibitory effects on prothrombinase assembly and function by interfering
in factor Xa-Va interaction [32]. It has also been found that the carboxy-terminus of the
factor Va heavy chain has a dramatic effect on its’ binding to factor Xa and prothrombin.
A factor Va molecule lacking the 27 amino acids at the carboxyl end of the heavy chain
produced by cleavage at Asp683 by the protease purified from the venom of the snake
Naja naja oxiana experienced a reduction in clotting activity. Additionally, this factor
Va variant (factor VaNO) was found to have a lower affinity for factor Xa within the
prothrombinase complex than wild-type factor Va with KD values of 4 nM and 0.5 nM,
respectively [33]. A pentapeptide (DYDYQ) consisting of the region Asp695-Gln699 was
also found to inhibit prothrombinase function by competitively inhibiting the
prothrombinase complex during thrombin formation with a Ki of 850 nM [34, 35].
1.6 FVa interaction with prothrombin/thrombin
There has been substantiated evidence that there are certain acidic amino acid
residues in the carboxyl-terminal end of the heavy chain of factor Va that are extremely
important for cofactor activity. The region between amino acids 680-709 has been the
basis for investigation into the functional role of factor Va in prothrombinase complex
formation and function [34, 36]. These acidic residues may be directly involved in the
interaction of the cofactor with factor Xa or Thrombin through positively charged amino
acids. It was recently demonstrated that there is a thrombin-binding site in the last 13
amino acids of the heavy chain.

Thrombin contains two electro-positively charged

binding regions (anion binding exosite I (ABE-I) and anion binding exosite II (ABE II)),
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which are crucial for protein function [37, 38]. ABE-I is responsible for binding many of
the proteins involved in the coagulation cascade including factors V, Va, fibrinogen,
PAR-I (the platelet thrombin receptor), thrombomodulin, and heparin cofactor II [39].
ABE-II, located just above the active site of the molecule, serves as a heparin-binding site
[40]. Factor Va will also bind to the second kringle domain of prothrombin to enhance
prothrombinase function [41]. Additional studies involving factor Va interactions with
prothrombin (fII) have implied that Cys539 of the heavy chain interacts with residues 473487 of the serine protease domain of factor II [42].

A peptide (N42R) consisting of

amino acid region 307-348 of the heavy chain of factor Va was found to be a good
inhibitor of prothrombinase with an IC50 value of 1.3 uM, leading to believe that this may
be a factor Xa and/or prothrombin binding site on factor Va [27]. Previous studies have
also demonstrated that a factor Va molecule cleaved initially with either cathepsin G
(fVaCG) or human neurtrophil elastase (fVaHNE) followed by cleavage with thrombin
giving rise to a factor Va molecule with a truncated heavy chain (fVCG/IIa or fVaHNE/IIa),
resulted in Kd values of ∼.2nM, similar to fVaIIa and kcat values that were higher than the
wild-type factor Va [43]. Surprisingly, clotting assays performed with these species in
the presence of factor V deficient plasma resulted in a loss of clotting activity of about
60%.
1.7 Prothrombin Activation
The activation of prothrombin to α-thrombin by factor Xa alone is not considered a very
efficient reaction. Factor Xa will convert prothrombin at a rate of 5 orders of
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Fig.1.3: Prothrombin Activation Pathway. Conversion of prothrombin to thrombin
occurs by two distinct pathways. Prothrombin can be activated by fXa alone, as shown in
pathway I or it can be converted to thrombin by the prothrombinase complex. Pathway I
will initially induce cleavage at Arg271 followed by cleavage at Arg320, to produce the
intermediates fragment 1.2 and prethrombin 2. Pathway II, which is essential for normal
clotting in healthy individuals, catalyzes an initial cleavage at Arg320, followed by
cleavage at Arg271 that produces the intermediate, meizothrombin.
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magnitude lower than when factor Va is incorporated into the prothrombinase complex
[44]. Factor Va promotes an increase in catalytic efficiency of prothrombinase along
with inducing sequential cleavage of Arg320 and Arg271 (Fig. 1.3). Both cleavages are
phospholipid-dependent, but only cleavage of Arg320 is dependent on factor Va. [45] [46].
The catalytic efficiency is highly improved as a result of decreasing Km by 100-fold and
increasing Kcat values by 3,000-fold, corresponding to substrate concentration and
enzyme efficiency, respectfully [47]. Kinetic analyses has revealed the Ca2+ dependent
interaction of factor Va with factor Xa, in solution, has a dissociation constant value (Kd)
of .8 μM, while the Kd in the presence of a phospholipid surface is decreased to1 nM,
showing a decrease of 1000-fold [15, 18].
The Kd value of the calcium-independent factor Va-prothrombin interaction is 1
μM.

Factor Va provides binding sites for proexosite 1 and the Gla domain of

prothrombin, explaining one of the possible mechanisms by which the cofactor functions
to increase enzyme efficiency [48]. It has been demonstrated that a factor V molecule
activated with the purified protease from the venom of the snake Naja nigricollis
nigricollis (NN) has reduced clotting activity and an increased Kd value of 4 nM when
compared to factor V activated with thrombin (fVaIIa) (Kd ∼0.5nM) [27]. When factor
VIIa is additionally cleaved by NN, cofactor activity is reduced by 60-80%. This reduction
in activity has been hypothesized to be a direct result from the loss of crucial amino acids
of the heavy chain that are released when cleaved by NN.
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1.8 Factor VLeiden
Disruptions in the coagulation cascade can lead to life-threatening circumstances, such as
bleeding and clotting disorders. Factor VLeiden is an autosomal dominant mutation in the
factor V gene that inhibits degradation of the molecule by APC [25] . This occurs
through a substitution of Arg506 by a glutamine that prevents proteolytic cleavage of the
cofactor by the APC/Protein S complex. Factor Va is inactivated by APC through three
sequential cleavages at Arg506, Arg306, and Arg679. In factor VaLeiden, cleavage of Arg506
does not occur, but cleavage at Arg306 and Arg679 cause inactivation of the cofactor at a
slower rate [49].

Studies have shown that cleavage at Arg506 promotes cleavage at the

other two sites for proper inactivation of the cofactor in order to prevent thrombosis [26].
Excessive venous clotting occurs from this disorder and eventually leads to a condition
known as deep venous thrombosis (DVT). Individuals with this syndrome are at risk of
pulmonary embolism that occurs when a venous blot clot dislodges and travels to the
lungs. Patients who are homozygous for the disease are more likely to suffer from these
episodes than heterozygous ones who only have one defective gene.
1.9 Thrombin Inhibition
Human alpha-thrombin is the main weapon in the battle to halt excessive
bleeding, after injury. In order for this process to be carried out effectively, all aspects of
the coagulation response must be tightly regulated. In cases where individuals suffer
from thrombotic disorders, the inhibition of thrombin is executed. Thrombin can be
inhibited directly through its catalytic active site and/or through its exosites [50]. One of
the main thrombin inhibitors used in medicine is heparin [51]. It indirectly inhibits
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thrombin by forming the heparin-thrombin-antithrombin complex, which involves
binding of heparin to exosite II of thrombin [52]. Direct inhibition of thrombin occurs
when an inhibitor binds to the active site of the enzyme or includes binding of one of the
exosites. Hirudin, a leech derived inhibitor, was one of the first discovered inhibitors of
exosite I.

It leads to the impairment of the enzyme to recognize some of its

macromolecular substrates by binding to both the active site and exosite I. Bothrojaracin,
isolated from a Brazilian snake vanom, is another thrombin inhibitor that will inhibit
both, exosites I and II [53]. In addition to outside inhibitors, thrombin can be inhibited
physiologically by antithrombin, once it forms a complex with a heparin sulfate [54].
Although there are a variety of antithrombotic drugs available, many of them lead to
undesirable side-effects and levels must constantly be monitored during therapy. It
would be of great advantage to develop alternative methods to aid individuals with
thrombotic tendencies.
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CHAPTER II
ROLE OF THE ACIDIC HIRUDIN-LIKE COOH-TERMINAL
AMINO ACID REGION OF FACTOR VA HEAVY CHAIN IN THE
ENHANCED FUNCTION OF PROTHROMBINASE
2.1 Abstract
Prothrombinase activates prothrombin through initial cleavage at Arg320 followed by
cleavage at Arg271. This pathway is characterized by the generation of an enzymatically
active transient intermediate, meizothrombin that has increased chromogenic substrate
activity but poor coagulant activity. The heavy chain of factor Va contains an acidic
region at the COOH-terminus (residues 680-709). We have shown that a pentapeptide
from this region (DYDYQ) inhibits prothrombin activation by prothrombinase by
inhibiting meizothrombin generation. To ascertain the function of these regions we have
created a mutant recombinant factor V molecule that is missing the last 30 amino acids
from the heavy chain (factor VΔ680-709) and a mutant molecule with the substitution
695

DYDY698→AAAA (factor V4A). The clotting activities of both recombinant mutant
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factor Va molecules were impaired compared to the clotting activity of wild type factor
Va (factor VaWt).

Using an assay employing purified reagents, we found that

prothrombinase assembled with factor VaΔ680-709 had a ~39% increase in the kcat, while
prothrombinase assembled with factor Va4A showed a ~20% increase in kcat for the
activation of prothrombin as compared to prothrombinase assembled with factor VaWt.
Gel electrophoresis analyzing prothrombin activation by prothrombinase assembled with
the mutant molecules revealed a delay in prothrombin activation with persistence of
meizothrombin. Our data do demonstrate that the COOH-terminal region of factor Va
heavy chain is indeed crucial for coordinated prothrombin activation by prothrombinase
because it regulates meizothrombin cleavage at Arg271 and suggest that this portion of the
molecule is partially responsible for the enhanced coagulant function of prothrombinase.
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2.2 Introduction
Blood coagulation is initiated at the site of vascular injury and results in the
activation of prothrombin to thrombin by the prothrombinase complex. Prothrombinase
is composed of the enzyme factor Xa bound to its cofactor, factor Va, on a phospholipid
surface in the presence of Ca2+ (1,2). Prothrombin and α-thrombin have two distinct
exosites (anion binding exosite I, ABE-I, and anion binding exosite II, ABE-II) that are
responsible for the functions of the molecules. The role of (pro)exosite I of thrombin
within prothrombinase is dependent on the incorporation of factor Va into the complex
as independently suggested by several laboratories (3-7). Two activation pathways for
prothrombin activation are possible: membrane-bound factor Xa alone activates
prothrombin following initial cleavage at Arg271 followed by cleavage at Arg320, while
the fully assembled prothrombinase complex activates prothrombin following the
opposite pathway, initial cleavage at Arg320 followed by cleavage at Arg271 (8-15).
Activation of prothrombin via this latter pathway is characterized by the generation of
an intermediate, meizothrombin, that has proteolytic activity and results in a significant
increase in the catalytic efficiency of factor Xa with respect to thrombin formation (16).
Initial cleavage of prothrombin at Arg320 that is absolutely factor Va-dependent and
results in meizothrombin generation is required and sufficient for the formation of the
active site of α-thrombin and complete exposure of ABE-I of the molecule (17-19).
However, meizothrombin does not have a fully exposed ABE-II which is required for
proper fibrinogen binding and timely fibrin formation. Exposure of this exosite, which
is partially covered by fragment 2 of prothrombin, requires cleavage at Arg271 (5,20,21).
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As a consequence, most functions associated with ABE-II of thrombin are impaired in
meizothrombin. For this reason, meizothrombin has reduced fibrinogen clotting activity
(22,23).
Human factor V circulates in plasma as a 330,000 single-chain protein that consists
of three domains in the order A1-A2-B-A3-C1-C2. Proteolytic cleavage of the cofactor
by α-thrombin occurs sequentially at Arg709, Arg1018, and Arg1045 to produce a
heterodimer consisting of a heavy chain (Mr~105,000) and a light chain (Mr~74,000)
associated through divalent metal ions (24-28) (Fig.2.1).

The heavy chain of the

cofactor contains an acidic amino acid region that has been shown to be important for
cofactor function (amino acid 680-709) (29). Early data have suggested that this region
is implicated in the productive interaction of factor Va with prothrombin (30-32).
Various proteases can cleave this acidic region to produce a cofactor with a truncated
heavy chain (33-36). Gerads et al first showed that it is possible to selectively eliminate
the acidic region from factor Va heavy chain by an enzyme purified from the venom of
the snake Naja Naja Oxiana (33). Using proteins of bovine origin, the authors showed
that while elimination of the COOH-terminal region of factor Va results in a molecule
with severely impaired clotting activity, incorporation of the truncated cofactor
molecule into prothrombinase resulted in an increased kcat for the activation of
prothrombin (33). The same authors also showed that cleavage of the human factor Va
heavy chain by the same enzyme results in a cofactor with impaired clotting activity
(33). Subsequently, Bakker et al using the same purified enzyme identified the cleavage
site of the enzyme at His682 in the human factor Va heavy chain (this amino acid is
conserved in the bovine cofactor) and demonstrated that prothrombinase assembled with
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a human factor Va molecule missing the Asp683-Arg709 portion has increased kcat for the
activation of prothrombin (34). Afterward, Camire et al using cathepsin G (CG) and
human neutrophil elastase demonstrated that prothrombinase assembled with factor Va
molecules missing the COOH-terminal domain of the heavy chain result in enzymes that
consistently express higher kcat values suggesting that these molecules are “more active”
cofactors than purified plasma factor Va activated with thrombin in an assay using
purified reagents (35). Surprisingly, and in line with the initial findings of Gerads et al
(33) the same factor Va molecules showed a significant decrease in clotting activity
(35). More recently, using a purified enzyme from the snake venom of Naja Naja
Nigricollis, we have also shown that a factor Va molecule missing a portion of the
COOH-terminus of the heavy chain has decreased clotting activity (36). Altogether
these studies reveal that removal of the acidic COOH-terminal portion of factor Va
heavy chain results in a cofactor molecule that is deficient in its clotting activity.
However, prothrombinase assembled with cofactor molecules missing the acidic
COOH-terminus produces significant higher kcat for prothrombin activation when
assessed in assays using purified reagents and a chromogenic substrate specific for
thrombin. A molecular explanation for these paradoxical observations has not yet been
provided.
We have recently used overlapping peptides from the region 680-709 of the factor
Va molecule to show that a pentapeptide with the sequence DYDYQ inhibits
prothrombin activation by prothrombinase in a competitive manner with respect to
substrate (36,37). We have further demonstrated that DYDYQ inhibits prothrombinase
activity by inhibiting meizothrombin generation (38).
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Using data obtained with

recombinant proteins, Toso and Camire have recently suggested that the COOHterminal region of the factor Va heavy chain has no detectable effect on prothrombinase
function (39).

This conclusion was surprising since their data showed that: 1)

prothrombinase assembled with recombinant factor Va molecules missing a portion or
the entire hirudin-like carboxyl- terminal end of the heavy chain have increased kcat for
the activation of prothrombin (from 129%-150%) compared to prothrombinase
assembled with the wild type molecule in an assay using purified reagents and a
chromogenic substrate specific for thrombin; 2) initial velocity measurements using the
same assay demonstrated a 20-25% increase in the rate of thrombin formation by
prothrombinase assembled with the same recombinant mutant cofactor molecules that
were truncated at their carboxyl-terminal end; and 3) a recombinant factor Va molecule
that is missing 17 amino acids from the carboxy-terminal portion of the heavy chain had
decreased clotting activity (39). All these data are in complete accord with all earlier
findings using plasma-derived factor Va molecules truncated at their heavy chain and
demonstrate a crucial but yet undetermined contribution of the acidic COOH-terminal
region of the heavy chain of the cofactor to prothrombinase activity during prothrombin
activation.
It has been well established that while meizothrombin has poor clotting activity, its
amidolytic activity is increased compared to thrombin towards small fluorescent and
chromogenic substrates specifically used to assess thrombin activity (23,40). A logical
hypothesis to reconcile all the findings described above is that the acidic COOH-terminus
of factor Va heavy chain, and more precisely the sequence DYDYQ, regulates
meizothrombin concentration during the factor Xa catalyzed prothrombin activation by
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prothrombinase. Thus, activation of prothrombin by prothrombinase assembled with a
cofactor that is missing the acidic region will result in increased and stable
meizothrombin production. This result will be translated by a factor Va molecule that is
deficient in its clotting activity but produces an increase in kcat when introduced into
prothrombinase.

In contrast, in the presence of an excess of the acidic region

(represented by DYDYQ, (36-38)) no meizothrombin is produced by prothrombinase
resulting in the generation of thrombin through the alternative pathway characterized by
initial cleavage of prothrombin at Arg271. The present work was undertaken to test these
hypotheses and to elucidate the role of the acidic COOH-terminal portion of factor Va
heavy chain during activation of prothrombin by prothrombinase.
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Figure 2.1. Mutants of human factor V. Factor V is activated following three
sequential cleavages by thrombin at Arg709, Arg1018, and Arg1545. These cleavages release
the active cofactor composed of heavy and light chains associated in the presence of
divalent metal ions, and two activation fragments. The COOH-terminus of the heavy
chain contains an acidic hirudin-like amino acid region that is important for its cofactor
functions. The mutations (deletions and point mutations) within the heavy chain are
indicated together with the designation for the recombinant mutant factor V molecules
created and used throughout the manuscript.
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2.3 Experimental Procedures
Diisopropyl-fluorophosphate (DFP), O-

Materials reagents, and proteins.
phenylenediamine

–dihydrochloride

(OPD),

N-[2-Hydroxyethyl]piperazine-N'-2-

ethanesulfonic acid (Hepes), Trizma (Tris base), and Coomassie Blue R-250 were
purchased from Sigma (St. Louis, Mo). Factor V-deficient plasma was from Research
Proteins

Inc

(Essex

Junction

VT).

L-α-phosphatidylserine

(PS)

and

phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL).

L-a-

Normal

reference plasma and the chromogenic substrate H-D-Hexahydrotyrosol-alanyl-arginyl-pnitroanilide diacetate (Spectrozyme-TH) were purchased from American Diagnostica Inc.
(Greenwich,

CT).

H-D-Phenylalanyl-L-pipecolyl-L-arginyl-p-nitroaniline

dihydrochloride (Chromogenix, S-2238) was purchased from Diapharma Group, Inc.
(West Chester, OH) and its concentration in solution (water) was verified as described
(41).

RecombiPlasTin for the clotting assays was purchased from Instrumentation

Laboratory Company (Lexington, MA). The reversible fluorescent α-thrombin inhibitor
dansylarginine N,N-(3-ethyl-1,5-pentanediyl)amide (DAPA), human prothrombin, RVVV activator, and human α-thrombin, were from Haematologic Technologies Inc. (Essex
Junction, VT). Active-site blocked human meizothrombin (obtained following digestion
of prothrombin with the purified component from the venom of the snake Echis
Carinatus as described (42,43), FPR-meizothrombin) was provided by Dr. Rick Jenny
(Haematologic Technologies Inc, Essex Junction VT).
Enzyme Research Laboratories (South Bend, IN).

Human factor Xa was from

Human cathepsin G was from

Calbiochem (EMD Chemicals, Inc. San Diego, CA). All molecular biology and tissue
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culture reagents and media were from Gibco, Invitrogen Corporation (Grand Island, NY).
Human plasma factor V was purified and concentrated using methodologies previously
described employing the monoclonal antibody αhFV#1 coupled to Sepharose (44).
Digestion of factor Va by a-thrombin and cathepsin G (to obtain factor VaII/CG) and/or the
purified enzyme from Naja Naja Nigricollis (factor VaNN) were performed as described
(35,36). The clotting activities of all factor Va preparations was measured by a clotting
assay using factor V deficient plasma and standardized to the percentage of control as
described (44) using an automated coagulation analyzer (START-4, Diagnostica Stago,
Parsippany, NJ). Recombinant wild type prothrombin and prothrombin rMZ-II that has
only one cleavage site for factor Xa (i.e. Arg320) were prepared and purified as previously
described (17,22,45,46). Phospholipid vesicles composed of 75% PC and 25% PS
(referred to as PCPS vesicles throughout the manuscript) were prepared as previously
described (47).
Construction of Recombinant FV Molecules.
substitutions

Mutant factor V with the

695

DYDY698→AAAA (factor V4A) was constructed using the QuickChange

II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the
manufacturer’s instructions with the following primers (underlined nucleotides represent
the mismatch): 5’-GATGAAGAGAGTGATGCTGCCGCTGCTGCCCAGAACAGA3’(sense)

and

5’-TCTGTTCTGGGCAGCAGCGGCAGCATCACTCTCTTCATC-3’

(anti-sense). The deletion mutant (factor VD680-709)) was constructed with the same kit.
Primers

for

VD680-709

factor

were

5’-

CCTCCAGAATCTACAGTCATGGCTACACGGTCATTCCGAAACTCATCATTGAA
TCAGG-3’

(sense)

and
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5’-

CCTGATTCAATGATGAGTTTCGGAACGACCGTGTAGCCATGACTGTAGATTCT
GGAGG-3’ (anti-sense). PCR products were transformed into competent E. Coli cells
and positive ampicillin-resistant clones were selected. Before transfection, all mutant
constructs were verified following sequencing in the Cleveland State University DNA
Analysis Facility using a Beckman Coulter CEQ 8000 Genetic Analysis System
(Beckman, Fullerton CA) with factor-V sequence-specific primers. The wild type pMT2FV and mutant pMT2-FV plasmids were isolated from the bacterial culture by the
QIAfilter High Speed plasmid Midi Kit (Qiagen Inc., Valencia, CA).
Expression of Recombinant Wild Type and Mutant Factor V in Mammalian
Cells. COS-7L and COS-7 cells (Invitrogen) were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, and
antibiotics (100 μg/ml streptomycin and 100 IU/ml penicillin) in a humidified
atmosphere of 5% CO2 and 95% air at 37°C. Purified factor VWt, factor VD680-709, and
factor V4A plasmids were transfected into the cells as described (48). Purification of all
recombinant factor V molecules was performed as described (49). The concentration of
all molecules was assessed by ELISA as detailed (48). The activity and integrity of the
recombinant molecules was verified before and after activation with RVV-V activator or
thrombin by clotting assays using factor V-deficient plasma and and in several
experiments by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
followed by Western blotting using monoclonal and polyclonal antibodies.
Analysis of Prothrombin Activation and FPR-Meizothrombin Cleavage at Arg271
by Gel Electrophoresis.

Prothrombin (1.4μM) was incubated with PCPS vesicles

(20μM), DAPA (50μM), and factor Va (10-30nM) in a buffer composed of 5 mM Ca2+ in
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20 mM Tris, 0.15 M NaCl, pH 7.4. The reaction was initiated with the addition of factor
Xa (0.5-1nM) at room temperature over a 1 h time course. Aliquots (50 μl ) from the
reaction were removed at selected time intervals (as indicated in the legend to the figures)
treated as described (38) and analyzed using 9.5% SDS-PAGE.

Prothrombin and

prothrombin-derived fragments were visualized by Coomassie Blue staining. Scanning
densitometry and calculation of the rates of prothrombin consumption were performed as
described (38,50,51). FPR-meizothrombin cleavage at Arg271 was assessed in a similar
manner.
Gel Electrophoresis and Western Blotting. SDS-PAGE analyses of recombinant
proteins following activation were performed using 5-15% gradient gels according to the
method of Laemmli (52). Proteins were transferred to polyvinylidene difluoride (PVDF)
membranes according to the method described by Towbin et al. (53). After transfer to
nitrocellulose, factor Va heavy and light chain(s) were detected using the appropriate
monoclonal and polyclonal antibodies (54-57).

Immunoreactive fragments were

visualized with chemiluminescence.
Measurement of Rates of Thrombin Formation in a Prothrombinase Assay.
rMZ-II and recombinant prothrombin were activated by prothrombinase prior to the
experiment using conditions previously described (58). Subsequent gel electrophoresis
analyses under reducing conditions were performed to verify that both rMZ-II and the
recombinant prothrombin preparations were activated to the same extent. The enzymes
(rMZ-IIa and recombinant a-thrombin) used for the titration of Spetrozyme-TH and S2238 were assayed at a constant concentration (4.3 nM), as previously described using
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serial dilutions of chromogenic substrate (35,50,59,60). The absorbance was monitored
with a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA).
Functionally defined apparent dissociation constants (KDapp) for factor Va binding to
factor Xa-PCPS were obtained from plots measuring the rate of thrombin generation as a
function of factor Va concentration in the presence of a limiting, (constant) concentration
of factor Xa. Throughout all experiments the assumption was n=moles of factor Xa
bound/mole of factor Va at saturation; throughout this study 1=1; the stoichiometry of the
factor Va-factor Xa interaction was fixed at 1. The initial rate of the formation of
thrombin (initial velocity in nM⋅IIa⋅min-1) was calculated, and the data were analyzed and
plotted using the software Prizm (Graphpad Software Inc, San Diego CA) according to
the one binding site model. Dissociation constants were extracted directly from the
graphs.
The assay using purified reagents and verifying the activity of the recombinant factor
V molecules was conducted under conditions where all factor Xa was saturated with
factor Va, as described by measuring α-thrombin formation by the change in the
absorbance of a chromogenic substrate at 405 nm (Spectrozyme-TH, 0.4 mM) (48). All
factor V molecules were activated with RVV-V or thrombin as described (36,37).
Knowing the (KDapp) of each factor Va species for factor Xa, the amount necessary to
saturate factor Xa was calculated using the quadratic equation described in the literature
(61,62) before each experiment.

The total concentration of ligand (VaT) used was

modified as appropriate to obtain between 95-98% saturation of the factor Xa molecule.
The absorbance was monitored with a Thermomax microplate reader and compared to an
α-thrombin standard prepared daily using purified plasma-derived α-thrombin (35,37,6139

63). The data were analyzed and plotted using the software Prizm according to the
Michaelis-Menten equation. Kinetic constants provided throughout the manuscript were
extracted directly from the graphs.

40

2.4 Results
Activation of Recombinant Human Factor V Molecules. To ascertain the function
of the acidic region from the COOH-terminus of factor Va heavy chain for cofactor
activity, we constructed a molecule that is missing the entire amino acid region 680-709
(factor VD680-709, Fig. 2.1). We have also constructed a factor V molecule with the
mutation 695DYDY698→AAAA (factor V4A). The recombinant molecules were expressed
in mammalian cells and purified to homogeneity as described (49). Because factor
VD(680-709) is missing Arg709 that is the activating cleavage site for thrombin (Fig.2.1), in
the functional assays, the recombinant mutant molecule was activated with RVV-V
activator.

In contrast, factor V4A was activated with either RVV-V activator or α-

thrombin. SDS-PAGE analyses followed by immunoblotting with specific monoclonal
antibodies to the heavy and light chain of the cofactor demonstrate that the mutant
recombinant proteins were intact and homogeneous and migrated according to their
expected molecular weights (Fig.2.2).
Cofactor Function of Recombinant Human Factor Va Molecules. Recent work
using recombinant factor Va molecules demonstrated that all cofactors lacking portions
or the entire acidic COOH-terminus of the heavy chain encompassing amino acid region
680-709, had KDapp values for membrane-bound factor Xa that are similar to the values
for the bimolecular interaction found with wild type or the intact plasma cofactor (39).
These values are similar to the KDapp obtained with truncated plasma-derived factor Va
molecules for factor Xa (35,36). Our studies with factor VaD(680-709) also demonstrate that
the mutant cofactor has similar affinity for plasma-derived factor Xa as the wild type
molecule (Fig.2.3A). Similar results were found for factor Va4A (not shown). Thus,
41

elimination of the acidic COOH-terminal region of factor Va heavy chain has no
consequence on the affinity of the cofactor for its interaction with factor Xa.
We next evaluated the ability of all recombinant factor Va molecules to function as a
cofactor for prothrombinase. A clotting assay using factor V-deficient plasma and a αthrombin generation assay using spectrozyme-TH and purified reagents were employed.
We have also followed the activation of prothrombin by gel electrophoresis. Figure 2.3B
show the fitted hyperbolic plots used to extract the kinetic constants obtained following
plasma-derived prothrombin activation by prothrombinase assembled with all control or
modified cofactor molecules, and summarized in Table 2.I. Because we wanted to
prevent the possibility that differences between prothrombinase assembled with factor
VaWt and prothrombinase assembled with factor VaD680-709) or factor Va4A may be
attributed to subtle differences in the KDapp of factor Va for factor Xa, which would result
in a lesser amount of prothrombinase formed, all experiments described below were
conducted under condition where more than 95% of factor Xa was saturated with factor
Va. The amount of factor Xa saturation by each cofactor was calculated using the
quadratic equation provided in the literature (61,62). The percent saturation of factor Xa
by each cofactor species as well as the correlation coefficient (R2) of the hyperbolas used
to extract the values of Vmax and Km, are provided in the legend to figure 2.3B together
with the actual reagent concentrations used in each experiment.
Factor VaRVVD680-709) had a 39.2% higher kcat (figure 2.3B, open circles) and 73%
lower clotting activity than factor VaRVVWt (figure 2.3B, open inverse triangles), while
factor VaIIa/CG had a 23.7% higher kcat and 62% lower clotting activity than factor
VaIIaPLASMA. In separate experiments, we have found that under similar experimental
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conditions, factor VaIIa/NN that has 60% lower clotting activity than the plasma cofactor
(36) had a 20.5% increased kcat than factor VaIIaPLASMA (Table 2.I). All these data are in
complete agreement with earlier and recent findings (33-36,39) and demonstrate that
elimination of the COOH-terminal region of factor Va heavy chain produces a molecule
with poor clotting activity yet, when the truncated cofactor is incorporated into
prothrombinase, it produces an enzyme with increased catalytic efficiency for
prothrombin activation as assessed in an assay using purified components and under
conditions in which the majority of membrane-bound cofactor is bound to factor Xa.
Overall the data shown in Table 2.I also demonstrate that the plasma and wild type
molecule behave similarly following activation by either RVV-V activator or a-thrombin
with respect to prothrombin activation. Thus, the two molecules are interchangeable and
throughout the manuscript control experiment were conducted with only one of the two
molecules as indicated.
We next assessed the capability of prothrombinase assembled with the truncated
molecules to activate prothrombin by gel electrophoresis and the data are presented in
figure 2.4.

Under the conditions employed, prothrombinase assembled with factor

VaRVVWt activates prothrombin quickly, with meizothrombin as a short-lived intermediate
as demonstrated by the brief half-life of fragment 1•2-A (Fig. 2.4A, panel A). Scanning
densitometry demonstrated a peak of meizothrombin early in the reaction at 80 sec and
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A
FVaWt

B
FVaΔ(680-709)

FVaWt

FVa4A

HCRVV-V

HCIIa
LCRVV-V

LCIIa

Figure 2.2. Electrophoretic analyses of wild type factor V and recombinant
factor V molecules. Panel A, factor VWt and factor V 680-709) were activated with RVV-V
activator as described (36); panel B, factor VWt and factor V4A were activated with
thrombin as described in the “Experimental Procedures” section and analyzed by SDSPAGE. Following transfer to a PVDF membrane, immunoreactive fragments were
detected with monoclonal antibodies αHFVaHC17 (recognizing an epitope on the heavy
chain of the cofactor between amino acid residues 307-506) and αHFVaHC9 (recognizing
the light chain). At the right the positions of the heavy/light chains of factor Va are
shown.
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Figure 2.3A. Raw data used for the determination of the parameters of
prothrombinase complex assembly and function. Panel A. Determination of the
affinity of recombinant factor Va molecules for plasma-derived factor Xa. Initial rates of
thrombin generation were determined as described under “Experimental Procedures”.
Prothrombinase assembled with factor VaWt is shown by filled squares (R2 = 0.979) while
prothrombinase assembled with FVaD(680-709) is depicted by filled triangles (R2 = 0.978)
Titrations were carried out to 20 nM factor Va; however, for graphical purposes the data
show the titration for up to 10 nM cofactor. The solid lines represent a nonlinear
regression fit of the data as detailed under “Experimental Procedures” using the software
Prizm and the model for one binding site. The apparent dissociation constant (KDapp) for
each species was derived from each titration performed at least in triplicate with at least
two different preparations of recombinant proteins and is listed in the inset.
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Figure 2.3B. Panel B. Determination of kinetic parameters of prothrombinase
assembled with various factor Va species. Initial rates of thrombin generation were
determined using the KD for factor Xa found in panel A as described under
“Experimental Procedures” in the presence of 20 uM PCPS vesicles. The reaction was
initiated by the addition of factor Xa (5 pM). Prothrombinase assembled with two
different concentrations of factor VaWtRVV is shown by open triangles (10 nM, 95% factor
Xa saturation, R2 = 0.97) and open inverse triangles (20 nM, 97% factor Xa saturation,
R2 = 97). Prothrombinase assembled with two different concentrations of factor VaD(680709)
is depicted by filled diamonds (10 nM, 96% factor Xa saturation, R2 = 0.98) and open
circles (20 nM, 98% factor Xa saturation, R2 = 0.99) while prothrombinase assembled
with factor VaIIaPLASMA is depicted by filled squares (10 nM, 98% factor Xa saturation, R2
= 0.97) and factor VaRVVPLASMA is shown by open diamonds (10 nM, 98% factor Xa
saturation, R2 = 0.97). Prothrombinase assembled with factor VaRVV4A is depicted by
filled inversed triangles (10 nM, 96.5% factor Xa saturation, R2 = 0.98). The values of
the Km and Vmax/ET (=kcat) extracted directly from these graphs are listed in Table 2.1.
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Specific
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550

1280 ±

NDe

663 ± 210 640 ± 120

114

c

Table 2.I Characteristics of various factor Va molecules when assembled into
prothrombinasea aThe rate of thrombin formation following activation of prothrombin by
prothrombinase assembled with the various factor Va species was calculated as described in the
“Experimental Procedures” section by knowing the dissociation constant of each factor Va
species for factor Xa. In each case more than 95% of factor Xa was saturated with factor Va.
Some of the data in the table were extracted directly from the graphs shown in figure 2.3B.
b

The rate of prothrombin consumption was determined following quantitative scanning
densitometry of several gels stained with Coomassie Blue as described in the “Experimental
Procedures” section. Some of the gels used are shown in figure 2.4.
c

All clotting activities were determined in a two-stage clotting assay following activation of factor
V species by RVV-V activator or α-thrombin as described (58,59).

d

Plasma factor V was activated with α-thrombin and treated with cathepsin G (CG) as described
(49).
e

The clotting activity of the truncated cofactor is ~50% that of plasma-derived factor Va (50).

ND, not determined in the present study.

47

no meizothrombin was detected following 180 sec (Fig.2.5). In contrast, in the presence
of prothrombinase assembled with factor VaD(680-709), prothrombin is activated with a rate
that is approximately 3-fold slower than the rate of activation by prothrombinase
assembled with the wild type molecule (Table 2.I), with persistence of meizothrombin as
indicated by the lingering of fragment 1•2-A even at the late time-points of the reaction
(Fig.2.4, panel B). The lower extent of prothrombin consumption most likely reflects the
result of product inhibition by the accumulating meizothrombin. Comparison of the data
shown in figures 2.4, panels A and B demonstrates that meizothrombin was produced
with similar initial rates but was more persistent. Scanning densitometry demonstrated a
peak of meizothrombin late in the reaction at 250 sec. Meizothrombin persisted for up to
6 minutes in the time course (Fig.2.5). In addition, appearance of the B chain is also
delayed when prothrombin is activated by prothrombinase assembled with factor VaD(680709)

, compared with the appearance of the B chain obtained following incubation of

prothrombin with factor VaRVVWt. Similar results were obtained with factor VaIIa/CG
(Table 2.I). In contrast, in the presence of DYDYQ, no meizothrombin is observed
following prothrombin activation by prothrombinase assembled with factor VaD(680-709)
and α-thrombin is formed through the alternate pathway characterized by initial cleavage
at Arg271 and formation of prethrombin 2 as intermediate (Fig.2.5, panel C). Overall, the
data demonstrate that elimination of amino acid region 680-709 from factor Va results in
a cofactor molecule that when incorporated into prothrombinase produces an enzyme
responsible for persistence of meizothrombin during activation of prothrombin.
In preliminary experiments using several preparations of recombinant proteins we
observed that while the truncated factor Va molecules are impaired in their clotting
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activity, factor Va4A is also deficient in its clotting activity. To understand the properties
of this molecule and the effect of the mutations on cofactor activity, we used the same
preparation of recombinant protein to perform three different experiments. Factor V4A
was first activated with α-thrombin and the solution was split into three separate samples.
One sample was used for assessment of clotting activity, one sample was used to measure
the kinetic parameters of prothrombinase assembled with saturating concentration of
factor VaIIa4A, and the third sample was used for analysis of prothrombin activation by gel
electrophoresis. The results reveal that while factor VaIIa4A is severely impaired in its
clotting activity (~22% that of factor VaIIaWt), prothrombinase assembled with the mutant
molecule shows a 19.7% increased kcat (Table 2.I). Gel electrophoresis followed by
scanning densitometry analysis demonstrated that prothrombinase assembled with factor
VaIIa4A activates prothrombin with a rate that is approximately 3.8-fold slower that the
rate of activation of prothrombin assembled with factor VaIIaWt (Fig.2.4 panels A andE,
Table 2.1). Scanning densitometry of several gels studying prothrombin activation by
prothrombinase assembled with factor VaIIa4A revealed a peak of meizothrombin at
approximately 240 sec with significant amounts of meizothrombin remaining for up to 10
minutes into the time course (not shown). These findings provide strong evidence in
favor of our previous conclusion that amino acid sequence 695-699, regulates
meizothrombin formation by prothrombinase (37,38). These data also demonstrate that,
in the presence of prothrombinase assembled with factor Va4A the excess meizothrombin
formed as assessed functionally by clotting assays can compensate for the absence of αthrombin in the assay using purified reagents because the increased amidolytic activity of
meizothrombin towards the chromogenic substrate is read as α-thrombin activity.
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Figure 2.4. Analysis of the activation of plasma-derived prothrombin by
prothrombinase. Plasma-derived prothrombin (1.4 uM) was incubated in different mixtures
with PCPS vesicles (20 nM), and prothrombinase assembled with either wild type factor Va
(panel A, 10 nM) or factor VaD(680-709) (panel B, 10 nM) as described in the “Experimental
Procedures” section. Panel C, prothrombinase assembled with factor Va 680-709) in the presence
of 20 uM DYDYQ (same conditions as in panel B); panel D, prothrombinase assembled with
plasma-derived factor Va (10 nM); panel E, prothrombinase assembled with factor Va4A (10 nM).
At selected time intervals aliquots of the reactions were withdrawn and treated as described in the
“Experimental Procedures” section. M represents the lane with the molecular weight markers
(from top to bottom): Mr 98,000, Mr 64,000, Mr 50,000, Mr 36,000, Mr 22,000. Lanes 1-19
represent samples from the reaction mixture before (0 min) the addition of factor Xa and 20 sec,
40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec, 220 sec, 240 sec, 5
min, 6 min, 10 min, 20 min, 30 min, and 60 min respectively following the addition of factor Xa.
The prothrombin derived fragments are shown as follows: II, prothrombin (amino acid residues 1579); prethrombin-1 (amino acid residues 156-579); F1•2-A, fragment 1•2-A chain (amino acid
residues 1-320); F1•2, fragment 1•2 (amino acid residues 1-271); P2, prethrombin-2 (amino acid
residues 272-579); P2’, prethrombin-2 cleaved at Arg284; B, B chain of α-thrombin (amino acid
residues 321-579).
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Figure 2.5. Reaction profiles for the activation of prothrombin by
prothrombinase. Progress curves for products and reactants for the activation of
prothrombin by prothrombinase assembled with factor VaWt (panel A) or factor VaD(680709)
(panel B) were obtained by quantitative densitometry of gels shown in Fig.2.4A and
2.4B, as described in the “Experimental Procedures” section. The graphs illustrate the
disappearance of prothrombin (filled squares), the transient formation of meizothrombin
(open circles), and the accumulation of the B chain of α-thrombin (filled circles). There
is a three-fold difference in the x-axis between the two panels, because prothrombinase
assembled with factor VaD(680-709) consumes prothrombin with a ~3-fold slower rate than
prothrombinase assembled with factor VaWt. The lines for the disappearance of
prothrombin were drawn according to the equation of a one phase exponential decay
(factor VaWt, R2 = 0.985, and factor VaD(680-709), R2 = 0.968). The lines depicting the
formation of meizothrombin and the accumulation of the B chain of α-thrombin were
arbitrarily drawn. Additional data points extending to 1h of incubation (shown in figure
4) have been omitted for clarity.
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Role of the Acidic COOH-terminal Portion of Factor Va Heavy Chain: a
Potential Mechanism. The data obtained thus far with the mutant cofactor molecules
indicate that meizothrombin is generated with similar rates, however the intermediate
accumulates to more persistent levels and lingers throughout the time course.
Appearance of the B-chain of α-thrombin also appears to be delayed when prothrombin is
activated

by

prothrombinase

assembled

with

the

mutant

cofactor

(Fig.2.5).

Consequently, analysis of the results suggests that cleavage of meizothrombin at Arg271
by prothrombinase assembled with factor VaRVVD(680-709) maybe be slower than cleavage
of meizothrombin at the same site by prothrombinase assembled with factor VaRVVWt
resulting in less conversion of meizothrombin to α-thrombin. Since during the course of
the assay using plasma-derived prothrombin we are measuring the sum of meizothrombin
and α-thrombin, a more rigorous test to verify which cleavage in prothrombin is affected
by the deletion at the COOH-terminus of factor Va heavy chain, involves the study of the
activation of a prothrombin molecule that cannot be cleaved at Arg271 such as rMZ-II
(22). In addition, while cleavage of rMZ-II can be followed by gel electrophoresis,
generation of rMZ-IIa can be also assessed with the chromogenic substrate used to assess
α-thrombin formation.

We thus followed activation of rMZ-II by prothrombinase

assembled with either factor VaRVVD(680-709) or factor VaRVVWt by gel electrophoresis (Fig.
2.6A) and activity assays using spetrozyme-TH (Fig.2.6B). Both sets of data demonstrate
that there are no significant differences between the rates of activation of rMZ-II by
either enzyme. The rates of rMZ-II consumption were similar as assessed by scanning
densitometry of the gels depicted in figure 2.6A (not shown), and the profiles of both
titrations are coincident (similar Vmax and similar Km values of 91±9 mM and 121±18
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mM, Fig.2.6B). Comparable results were found in two independent measurements using
two different preparations of recombinant factor Va molecules and two separate
preparations of rMZ-II. The data demonstrate that cleavage at Arg320 in prothrombin is
not affected by the COOH-terminal portion of factor Va heavy chain.
Earlier data has demonstrated that incorporation of factor Va in prothrombinase has a
differential influence on the rates of cleavage of the two bonds responsible for the
activation of prothrombin. In particular, the binding of factor Va to factor Xa within
prothrombinase results in an 3-5-fold increase in the rate of cleavage of meizothrombin at
Arg271 as compared to cleavage at the same site by factor Xa alone (13,14). We next
compared the rate of cleavage of FPR-meizothrombin at Arg271 by prothrombinase
assembled with various factor Va molecules (Fig.2.7). The data demonstrate a delay for
cleavage of FPR-meizothrombin at Arg271 by prothrombinase assembled with factor
VaRVVD(680-709) (panel C) or factor VaRVV4A (panel D) as compared to the same reaction
catalyzed by prothrombinase assembled with factor VaRVVPLASMA (panel B). A direct
comparison between the rates of cleavage of FPR-meizothrombin by membrane-bound
factor Xa alone (panel A) and cleavage of the substrate by prothrombinase assembled
with factor VaRVVD680-709) (panel C) or factor Va4A do not show any significant
differences.

These data imply that following incorporation of factor Va in

prothrombinase it is the COOH-terminal acidic hirudin-like portion of factor Va heavy
chain and in particular amino acid sequence

695

DYDY698 that is responsible for the

increase in the rate of cleavage of meizothrombin at Arg271. Quantitative scanning
densitometry of fragment 1•2-A present on the gels shown in figure 2.7, demonstrated a
~3-4-fold delay in cleavage of FPR-meizothrombin at Arg271 by either membrane-bound
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factor Xa alone or prothrombinase assembled with the recombinant mutant factor Va
molecules, compared to cleavage at Arg271 by prothrombinase assembled with the
plasma-derived cofactor (Fig.2.7, panel E). These data are in complete agreement with
previous findings (13,14) and demonstrate that the lingering of meizothrombin during
plasma-derived prothrombin activation by prothrombinase assembled with factor
VaRVVD680-709) or factor Va4A is the result of impaired cleavage at Arg271. Overall, the
data suggest that amino acid sequence

695

DYDY698, regulates meizothrombin

concentration during activation of prothrombin by prothrombinase.
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Figure 2.6A. Analysis of the activation of rMZ-II. Panel A. Gel electrophoresis analyses.
rMZ-II (1.4 µM) was incubated in different mixtures with PCPS vesicles (20 µM), DAPA (3
µM), and factor VaWt (left panel, 20nM) or factor VaD(680-709) (right panel, 20nM). The reaction
was started by the addition of factor Xa and the samples were treated as detailed in the
“Experimental Procedures” section. Lanes 1-9, represent samples of the reaction mixture
following incubation of prothrombinase with rMZ-II, before (lane 1), or following 0.5 min, 1
min, 2.5 min, 4min, 6min, 10min, 20min, and 30min incubation with factor Xa respectively.
Positions of prothrombin-derived fragments are indicated at right as detailed in the legend to
figure2.4. For the easy reading of the manuscript, the factor Va species used for the
reconstitution of prothrombinase are shown under each panel.
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Figure 2.6B. Kinetic analyses of the activation of rMZ-II. Initial rates of α-thrombin
generation were determined as described under “Experimental Procedures” and the data were
plotted according to the Michaelis-Menten equation. Activation of rMZ-II by prothrombinase
assembled with factor VaWt is shown by filled squares (R2 = 0.98) while activation of rMZ-II by
prothrombinase assembled with factor Va D(680-709) is depicted by filled triangles (R2 = 0.96).
Kinetic constants reported in the text were extracted directly from the graphs.
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Figure 2.7. Gel electrophoresis analyses for cleavage of FPR-meizothrombin. FPRmeizothrombin (1.4 µM) was incubated in different mixtures with PCPS vesicles (20 µM) and
factor Va as described in the legend to figure 2.4. The reaction and the samples were further
treated as detailed in the “Experimental Procedures” section. The gels were scanned and
quantification of fragment 1•2-A was performed as described (65, 66). Panel A, control, no
factor Va (13.4 moles FPR-meizo consumed•s-1•mole factor Xa-1); panel B, factor VaRVVPLASMA
(42.6 moles FPR-meizo consumed•s-1•mole factor Xa-1); panel C, factor VaRVVD(680-709) (8.4 moles
FPR-meizo consumed•s-1•mole factor Xa-1); panel D, factor VaRVV4A (14.6 moles FPR-meizo
consumed•s-1•mole factor Xa-1). M represents the lane with the molecular weight markers (from
top to bottom): Mr 50,000, Mr 36,000, Mr 22,000. Lanes 1-19 represent samples from the
reaction mixture before (0 min) the addition of factor Xa and 20 sec, 40 sec, 60 sec, 80 sec, 100
sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec, 220 sec, 240 sec, 5 min, 6 min, 10 min, 20 min,
30 min, and 60 min respectively following the addition of factor Xa. The prothrombin derived
fragments are shown as detailed in the legend to figure 2.4. For the easy reading of the
manuscript, the factor Va species used for the reconstitution of prothrombinase are also shown
under each panel.
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2.5 Discussion
Our data demonstrate that the acidic COOH-terminus of factor Va heavy chain is
responsible for coordinate activation of prothrombin resulting in timely a-thrombin
formation at the place of vascular injury. Furthermore, our findings appear to resolve
many apparently conflicting results and explain the observation that was initially reported
15 years ago (33) and verified several times with either truncated plasma-derived factor
Va (34-36) or more recently with recombinant factor Va molecules (39).

Namely,

incorporation of cofactor molecules with a truncated heavy chain into prothrombinase
results in enhanced stability of meizothrombin during prothrombin activation.

Our

findings assign an important physiological role to the COOH-terminus of factor Va heavy
chain for efficient prothrombin activation and demonstrate that the sequence 695DYDY698,
regulates meizothrombin formation by factor Xa within prothrombinase. In addition, we
have recently demonstrated that meizothrombin formation by prothrombinase assembled
with the plasma-derived cofactor is inhibited in the presence of an excess of an acidic
region from the carboxyl-terminal portion of factor Va (represented by mM
concentrations of DYDYQ).

Since meizothrombin formation by prothrombinase

assembled with factor VaD(680-709) is also completely inhibited by an excess of DYDYQ,
the combined findings demonstrate that this amino acid sequence is solely responsible for
the regulation of meizothrombin processing, and provide a logical explanation for the
anticoagulant effect of the DYDYQ peptide, (explicitly, the acidic pentapeptide controls
meizothrombin concentration during prothrombin activation). Keeping in mind the data
shown in figure 2.7, we can thus speculate that DYDYQ inhibits meizothrombin
generation by accelerating the cleavage rate at Arg271. These findings are in complete
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accord with our recent data demonstrating that DYDYQ increases the rate of cleavage of
prothrombin by factor Xa alone with accumulation of prethrombin 2 (38), and warrant the
need for further investigation of the mode of action and site of interaction with
prothrombin of the pentapeptide as well as of the molecular mechanism of inhibition of
prothrombinase by DYDYQ.
Approximately 35 years ago Heldebrant and Mann first demonstrated that incubation
of fragment 2 with α-thrombin results in a significant increase in the esterolytic activity
of the enzyme towards Tos-L-Arg-OMe (TAME) as compared to the activity of αthrombin alone towards the same substrate (66). This increase in the esterase activity of
a-thrombin was concomitant with a decrease in its clotting activity (66). Subsequently,
Franza et al (65), Morita et al (67) and Kornalik and Blombäck (68) reported that
meizothrombin (and meizothrombin desfragment 1) generated by a component purified
from the venom of Echis Carinatus has poor clotting activity and very high hydrolytic
activity towards TAME. Franza et al specifically demonstrated that the meizothrombin
species generated by Echis Carinatus has much higher hydrolytic activity towards TAME
than α-thrombin (between 30-50% higher activity) (65). Concomitantly, Myrmel et al
provided complete evidence demonstrating that addition of fragment 2 to α-thrombin
increases significantly the catalytic efficiency of the enzyme towards TAME, compared
to the efficiency of α-thrombin alone against the same substrate (69). All these findings
were later corroborated by two independent studies using either TAME or S-2238 that
reported that meizothrombin has higher catalytic efficiency than α-thrombin towards
small peptidyl substrates (43,70), and it was hypothesized that there may be subtle but
significant differences between the active sites of α-thrombin and meizothrombin (70).
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This conclusion was strengthened by earlier findings demonstrating that while DAPA
interacts with prethrombin 2 with an affinity that is ~30-times lower than that for αthrombin, the inhibitor doesn’t bind prothrombin and prethrombin 1 (64), suggesting an
important effect of cleavage at Arg271 on the progressive formation of the active-site of αthrombin. More recently, using electron spin resonance to probe the active sites of
meizothrombin and α-thrombin, significant conformational differences between the
apolar binding region of the active-site of the two enzymes have been reported (71).
Abundant structural data obtained in recent years from the crystal structure of several
prothrombin derivatives, has established that meizothrombin is impaired in its clotting
activity because it has not yet exposed ABE-II (which is covered by fragment 2).
Exposure of this site that is required for optimum fibrinogen binding and processing,
necessitates cleavage of meizothrombin at Arg271 resulting in the release of fragment 2
(5,20,21,72).

Several studies have shown independently that plasma-derived or

recombinant meizothrombin has 25-60% higher catalytic efficiency towards S-2238
(15,23,40,73,74) or TAME (43), and 25-50% higher fluorescence intensity with DAPA
(14,64).

The data shown in Fig.2.6B confirm all previous findings obtained using

recombinant or plasma-derived meizothrombin, and demonstrate that rMZ-IIa has higher
catalytic efficiency than α-thrombin towards the peptidyl substrates generally used to
assess for α-thrombin activity (75-77). At this point, it is important to underline the fact
that while a sulfated peptide representing the last 12 amino acids of hirudin (Hir54-65(SO3)) is a very potent inhibitor of α-thrombin’s function in vivo and in vitro because it
interacts with ABE-I of the enzyme with high affinity (78), the dodecapeptide increases
considerably the activity of α-thrombin towards peptidyl chromogenic substrates
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(between 30%-50%, (4,79)).

The correlation of this observation with the increased

activity of meizothrombin towards small peptidyl chromogenic and fluorescent substrates
as compared to the activity of α-thrombin alone against the same synthetic substrates
remains to be established. Nevertheless, the bulk of published data strongly supports the
concept that any interaction of ABE-I and/or ABE-II of α-thrombin with their respective
ligands will result in allosteric modulations of the active site of the enzyme (80,81). It is
thus expected that meizothrombin as well as meizothrombin desfragment 1 (ABE-II
occupied by fragment 2) may have a different configuration of the active-site than the
active-site of α-thrombin.
Blood clotting enzymes, with the exception of factor IX and prothrombin, are
activated following single proteolytic cleavage (1).

It is thus assumed that results

obtained following the activation of a zymogen either by gel electrophoresis or by assays
that measure the generation of enzymatic activity with chromogenic substrates should be
concordant.

However, prothrombin activation is different from other zymogens

activation because: 1) prothrombin can be activated through two different pathways that
have different requirements and significantly different rates; and 2) activation of
prothrombin through the meizothrombin pathway generates an intermediate that has
higher amidolytic activity than α-thrombin towards chromogenic substrates that are used
to assess for a-thrombin generation. Thus, while following prothrombin activation by
both gel electrophoresis and activity assays simultaneously may appear to be a
duplication of the same result, drawing conclusions from activity assays alone without
analyzing the pathway to prothrombin activation and the intermediates formed, is an
oversimplification that can lead to erroneous conclusions.
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Two assays are used worldwide for the determination of factor Va cofactor activity: a
clotting assay using factor V-deficient plasma and an assay using purified reagents. The
former assay is performed at low (limiting) concentrations of factor Va, while the latter
assay is conducted with high (saturating) concentrations of factor Va with respect to
factor Xa. Both assays indirectly report on factor Va cofactor activity through the
activation of prothrombin to α-thrombin assuming that α-thrombin is the final and main
product of the reaction. The clotting time measures fibrin formation in factor V-deficient
plasma, while the prothrombinase assay measures α-thrombin’s amidolytic activity as it
is generated towards a chromogenic substrate. Initial cleavage of prothrombin at Arg320
by prothrombinase, which is absolutely factor Va-dependent, results in rapid
meizothrombin generation. Depending on the ratio of meizothrombin to α-thrombin
formed at the moment the measurement is taken, the results reflect the clotting or
amidolytic activity of either α-thrombin, or meizothrombin, or the sum of both. Thus, if
generation of α-thrombin is slower than formation of meizothrombin, the measurements
will mostly reflect the properties of meizothrombin (i.e. impaired clotting and increased
chromogenic activity).
Work performed independently in several laboratories worldwide has demonstrated
that while elimination of the COOH-terminal region of factor Va heavy chain results in a
cofactor molecule with poor clotting activity (retaining 20-40% clotting activity of
normal factor Va), the same molecule as part of prothrombinase produces a substantial
increase in the kcat of the enzyme in an assay using a chromogenic substrate to assess αthrombin generation (33-36) (Table 2.II). Similar results were recently obtained with
recombinant factor Va molecules missing portions of the COOH-terminus of factor Va
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heavy chain (39). All these results could be partially explained if the truncated cofactor
molecules had diminished binding capabilities for membrane-bound factor Xa. However,
earlier data has demonstrated that all truncated factor Va molecules have similar KD for
factor Xa as the plasma-derived cofactor (35,36), and recent experiments with
recombinant factor Va molecules missing the entire hirudin-like COOH-terminal portion
of factor Va heavy chain (amino acids 679-709, rFVa678) confirm our findings shown in
Fig.2.3A with factor VaD(680-709), and demonstrate that the recombinant mutant cofactor
binds factor Xa with similar affinity as the wild type molecule (39). Thus, while every
study performed (worldwide) was remarkably consistent in showing poor clotting and
increased kcat for the same truncated factor Va molecules (up to ~50% higher kcat, Table
2.II), no satisfactory explanation has been yet provided to explain this seeming paradox at
best (33-35), or at worst the observations were simply discarded as relatively modest
changes (39). Our data, put in the context of the literature, provide a logical explanation
for these observations and clearly demonstrate that the acidic COOH-terminal portion of
factor Va heavy chain controls the rate of α-thrombin generation by factor Xa within
prothrombinase.
Crystallographic evidence has determined that cleavage at Arg320 in prothrombin is
required to induce the conformational transitions for the conversion of the zymogen to
proteinase (82,83). In meizothrombin, the two factor Xa cleavage sites are separated by
36 Å (21). Before cleavage at Arg320, the two cleavage sites in prethrombin 1 are
separated by 42 Å (79). These combined findings alone verify the change in
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Table 2.II
Summary of results obtained with factor Va molecules truncated at the COOHterminus of the heavy chain in a clotting assay and in a prothrombinase assay

Impaired Clottinga

Increased kcatb

Gerads et al (ref.18)

+

+ (17%)c

Bakker et al (ref.19)

+d

+ (12%)e

Camire et al (ref.20)

+

+ (18-23%)

Kalafatis et al (ref.21)

+

+ (19%)f

Toso and Camire (ref.37)

+

+ (29-50%)g

a

The plus sign indicates that the molecules missing part or the entire COOH-terminal
portion of the heavy chain are impaired in clotting activity.

b

The plus sign indicates that the factor Va molecules missing part or the entire COOHterminal portion of the heavy chain have increase catalytic efficiency when assembled in
prothrombinase. In parenthesis is the % increase in kcat compared to prothrombinase
assembled with plasma-derived factor Va or to wild type recombinant factor Va reported
in each study.
c

All results reported were obtained with proteins of bovine origin.

d

From reference 18; the authors also report results obtained with human factor Va and
clotting assays with factor V-deficient plasma
e

All work was performed with proteins of human origin and are complementary to the
work reported in reference 18.
f

The kcat of factor VaIIa/NN in the assay for using purified reagents and a chromogenic

substrate to assess for α-thrombin formation is reported in the present manuscript (Table
2.I)gAll results were obtained with recombinant proteins. The factor V construct used
expression was missing a major portion of the B domain of the molecule.
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conformation associated with cleavage of prothrombin at Arg320 since we can expect that
the two scissile bonds are separated by ~42 Å in intact prothrombin. We show that while
rMZ-II is cleaved with equivalent rates by either, prothrombinase assembled with factor
VaWt or prothrombinase made with factor VaD(680-709), active-site blocked meizothrombin
was processed with a slower rate by prothrombinase assembled with factor VaD(680-709) or
factor Va4A, compared to prothrombinase assembled with factor VaPLASMA. Altogether,
these findings demonstrate that the rate of the first cleavage in prothrombin (i.e. Arg320)
does not appear to be significantly affected by the deletion of the COOH-terminal portion
of factor Va heavy chain. The data rather suggest that in the presence of prothrombinase
assembled with factor VaD(680-709) (or factor Va4A), meizothrombin has a different
conformation than meizothrombin formed by prothrombinase assembled with factor VaWt
since the molecule is not cleaved with equivalent rates by the two enzymes. These data
confirm earlier findings showing a 4-5-fold increase in the rate of cleavage of
meizothrombin by prothrombinase at Arg271 as compared to cleavage of the same
substrate by factor Xa alone (13,14), and clearly demonstrate that the COOH-terminal
acid region from factor Va heavy chain alone is responsible for the acceleration of the
rate of cleavage of prothrombin at Arg271 by prothrombinase.
Recently, it has been shown that following cleavage at Arg320, meizothrombin
undergoes ratcheting prior to cleavage at Arg271, whereby, meizothrombin changes
conformation prior to subsequent processing to product by prothrombinase (84). A
prothrombin

molecule

with

the

mutations

Ile321-Val322-Glu323→Thr-Ala-Thr

(prothrombinTAT) was impaired in the ratcheting process and meizothrombinTAT persisted
throughout the prothrombinase-mediated activation process. Remarkably, these latter
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data resemble our data shown in figure 2.4 Panels B and E obtained with factor
VaRVVD(680-709) and factor VaIIa4A. However, ratcheting and efficient cleavage at Arg271 in
meizothrombinTAT could be restored in the presence of an excess of DAPA (64,84),
implying that the active site of meizothrombin is involved in the conformational change
of the molecule required for efficient cleavage at Arg271. Furthermore, an incomplete
conversion of conformationally activated prothrombin bound to FPRck, from zymogen to
proteinase, was observed in the presence of an excess of DAPA , most likely because
DAPA interaction with the active-site involves both the site occupied by FPR-ck and the
site that is available on prethrombin 2 (64) in order for the complete transition
(ratcheting) to occur.

Since it is not clear yet whether it is the ratcheting of

meizothrombin from the zymogen to proteinase form, or cleavage at Arg271 per se, or
both, that induce a change in the active site of α-thrombin resulting in an enzyme with
diminished kcat for peptidyl chromogenic and fluorescent substrates as compared to
meizothrombin, our data put in the context of the literature suggest that slow ratcheting
and/or impaired cleavage at Arg271 are the cause of meizothrombin lingering during
activation of prothrombin by prothrombinase assembled with factor VaRVVD680-709).
Our data provide strong evidence pointing to the fact that the COOH-terminal acidic
region of factor Va heavy chain is crucial for efficient α-thrombin generation at the place
of vascular injury.

Bearing in mind the poor fibrinogen clotting properties of

meizothrombin, we can hypothesize that following injury individuals with a factor Va
molecule lacking the COOH-terminal region of the heavy chain will produce more
meizothrombin, rather than α-thrombin at the place of vascular injury resulting in
bleeding tendencies. This hypothetical situation is verified by clinical data obtained from
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patients that are homozygous for an amino acid substitution in the prothrombin gene at
Arg271 (85-89). All these patients that have a prothrombin molecule unable to be cleaved
at Arg271 circulating in their plasma, were identified because of their hemorrhagic
syndrome clinically resembling mild hemophilia.

Thus, while meizothrombin can

competently substitute for most of α-thrombin’s procoagulant/anticoagulant functions
locally at the place of vascular injury in the presence of an adequate membrane surface
(22,40,58,90-93), the molecule still lacks the ultimate procoagulant function (i.e. efficient
fibrin formation). All these observations together with the fact that prothrombin can be
activated through two distinct pathways that differ in terms of rate constants and
intermediates, may allow for the design of novel anticoagulant molecules with the
potential to act as a control switch and able to modulate specific events during αthrombin (and meizothrombin) formation according to a precise need. DYDYQ may be
the prototype for such a class of anticoagulants and we have recently reported that
DYDYQ inhibits prothrombin activation on the surface of endothelial cells (79) attesting
of its physiological potency. Thus, if the requirement for anticoagulant therapy is to slow
down generation of α-thrombin activity without eliminating its production, a low
concentration of DYDYQ will be enough to alleviate α-thrombin formation through the
meizothrombin pathway (38). In contrast, if complete arrest of α-thrombin formation is
required, higher concentrations of DYDYQ will completely eliminate α-thrombin
generation through the prethrombin 2 pathway as well. In conclusion, pentapeptide
DYDYQ provides an ideal backbone for exosite directed anticoagulant molecules that
could attenuate or fully suppress α-thrombin formation in individuals with thrombotic
tendencies.
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Chapter III
AMINO ACID REGION 659-663 OF FACTOR VA HEAVY CHAIN IS
INDISPENSABLE FOR OPTIMAL ACTIVITY OF FACTOR XA
WITHIN PROTHROMBINASE

3.1 Abstract
Factor Va, the cofactor of prothrombinase, is composed of heavy and light chains
associated non-covalently in the presence of divalent metal ions. The COOH-terminal
region of the heavy chain contains acidic amino acid clusters that are important for
cofactor activity. We have investigated the role of amino acid region 659-663 that
contains five consecutive acidic amino acid residues. To ascertain the function of this
region site-directed mutagenesis was performed to generate factor V molecules in which
all residues were mutated to either lysine (factor V5K) or alanine (factor V5A). We have
also constructed a mutant molecule with this region deleted (factor VΔ659-663).

The

recombinant molecules along with wild type factor V (factor VWT) were transiently
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expressed in COS7L cells, purified, and assessed for cofactor activity.

Two-stage

clotting assays revealed that the mutant molecules had reduced clotting activities
compared to factor VaWT. Kinetic analyses studying prothrombinase assembled with the
mutant molecules demonstrated diminished kcat values, while the affinity of all mutant
molecules for factor plasma-derived Xa was similar to factor VaWT. Gel electrophoresis
analyzing plasma-derived and recombinant mutant prothrombin activation demonstrated
delayed cleavage of prothrombin at both Arg320 and Arg271 by prothrombinase assembled
with the mutant molecules. However, cleavage at Arg271 by prothrombinase assembled
with factor VaΔ659-663, factor Va5K and factor V5A was slower compared to cleavage at
Arg320 by prothrombinase assembled with the same recombinant cofactor molecules,
resulting in lingering of meizothrombin throughout the activation process. These results
were confirmed following analysis of the cleavage of FPR-meizothrombin by
prothrombinase assembled with the mutant cofactor molecules. Our data suggest that
amino acid region 659-663 from factor Va heavy chain plays an important role during
prothrombin activation by prothrombinase.
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3.2 Introduction
The proteolytic conversion of prothrombin to thrombin is catalyzed by the
prothrombinase complex composed of the enzyme, factor Xa, and the cofactor, factor Va,
assembled on a membrane surface in the presence of Ca2+ (1, 2). Factor Xa alone can
activate prothrombin following sequential cleavages at Arg271 and Arg320 yielding the
transient inactive intermediate prethrombin 2. However, the interaction of factor Va with
factor Xa on a membrane/cell surface in the presence of divalent metal ions and
formation of the prothrombinase complex results in the reversal of the order of cleavages
and a 300,000-fold increase in the catalytic efficiency of factor Xa for thrombin
generation. A first cleavage of prothrombin by prothrombinase at Arg320 produces the
active intermediate meizothrombin, while the second cleavage at Arg271 produces
thrombin (3-6).

Thrombin and prothrombin contain two positively charged binding

regions (anion binding exosite I, ABE-I and anion binding exosite II, ABE II), that are
crucial for protein function. Initial cleavage of prothrombin at Arg320 by prothrombinase
which is absolutely factor Va dependent, entirely exposes (pro)exosite I (7). Factor Va is
required for the specific recognition of prothrombinase by (pro)exosite I of prothrombin
(8, 9). Proteolytic elimination of fragment 1 of prothrombin eliminates the accelerating
effect of the membrane surface for initial cleavage at Arg320 by prothrombinase (10, 11).
Coagulation factor V circulates in plasma at a concentration of 20 nM, as a single
chain inactive precursor of Mr 330,000 consisting of three subdomains in the order A1A2-B-A3-C1-C2) (Fig.3.1). The molecule is activated by thrombin following sequential
cleavages at Arg709, Arg1018, and Arg1545 to generate the active cofactor (factor Va)
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composed of a heavy chain of Mr 105,000 (A1-A2 domains) and a light chain of Mr
74,000 (A3-C1-C2 domains). The two chains are associated via non-covalent bonds in
the presence of divalent metal ions (12). The light chain contains the domains that
interact with the cell membrane surface at the place of vascular injury while the heavy
chain possesses specific amino acid motifs that are involved in prothrombinase complex
formation and function. We have demonstrated that a binding site for factor Xa is
contained within the heavy chain of the cofactor (13, 14) and we have recently shown
that two residues from the central portion of the heavy chain of factor Va (amino acid
residues 334-335) are crucial for cofactor function (15).
The COOH-terminal region of factor Va heavy chain is involved in the interaction
with prothrombin (16, 17). We have recently demonstrated that a factor Va molecule
lacking the last 30 amino acids from the carboxyl-terminal end of the heavy chain (amino
acid residues 680-709) displayed a reduction in clotting activity and a delay in
prothrombin

consumption,

leading

to

the

accumulation

of

the

intermediate

meizothrombin during prothrombin activation. Prothrombinase assembled with the same
mutant also demonstrated an increased kcat for prothrombin activation when compared to
prothrombinase assembled with wild-type factor Va (18). We have established that this
acidic region is essential for optimal expression of cofactor activity because it promotes a
productive interaction with prothrombin regulating the rate of cleavage at Arg271 by
prothrombinase (18-21). This region of the cofactor is highly acidic in nature and
contains several tyrosine residues that have been shown to be involved in factor V
activation by α-thrombin and proper cofactor function (22). This part of the molecule
and, more precisely, the motif DYDYQ (amino acid residues 695-699) is highly
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conserved in 20 different mammal species (Fig.3.2). The heavy chain of the cofactor
contains another cluster of acidic amino acids (DDDED, amino acid region 659-663) that
may also be involved in the regulation of prothrombinase activity. This region is also
conserved among species a likely indicator of its physiological significance (Fig.3.2).
The present study was undertaken to evaluate the importance of amino acid region 659663 of factor Va heavy chain for prothrombinase complex assembly and function. Our
results show that this region exerts a profound and unexpected effect on prothrombin
activation by prothrombinase.
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Figure 3.1. Factor V structure and mutant Molecules. The procofactor, factor V, is
composed of three A domains (red), a connecting B region, and two C domains (blue).
Factor Va is generated following three sequential cleavages of factor V by α-thrombin at
709

1018

1545

Arg , Arg , and Arg . The mutations within the acidic, hirudin-like COOHterminus region of the heavy chain (amino acid residues 659-653), are indicated together
with the designation of the recombinant mutant factor V molecules created and used
throughout the manuscript. The acidic region 680-709, recently shown to be involved in
factor Va cofactor function is also illustrated (18).
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Figure 3.2. Comparison of the acidic COOH-terminal amino acid sequences 659663 and 695-698 from factor Va heavy chain among species (numbering from the
human molecule, top sequence). Sequences were derived from various database
sources, such as GenBank and the NCBI Trace Archive. The species shown are as
follows (from top to bottom): Homo sapiens, human; Pan troglodytes, chimpanzee;
Pongo pygmaeus, orangutan; Nomascus leucogenys, white-cheeked gibbon; Macaca
mulatta, rhesus monkey; Papio hamadryas, hamadryas baboon; Callithrix jacchus, whitetufted-ear marmoset; Otolemur garnettii, small-eared galago; Bos taurus, cattle; Sus
scrofa, pig; Canis lupus familiaris, dog; Myotis lucifugus, little brown bat; Equus
caballus horse; Dasypus novemcinctus, nine-banded armadillo; Loxodonta africana,
African elephant; Dipodomys ordii, Ord’s kangaroo rat; Oryctolagus cuniculus, rabbit;
Cavia porcellus, domestic guinea pig; Mus musculus, western European house mouse;
Rattus norvegicus, Norway rat.
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3.3 Experimental Procedures
Materials

and

Reagents.

Diisopropyl-fluorophosphate

(DFP),

O-

phenylenediamine (OPD)-dihydrochloride, and Coomassie Blue R-250, were purchased
from Sigma (St. Louis, MO). Factor V-deficient plasma was from Research Protein Inc.
(Essex Junction, VT). Secondary anti-mouse and anti-sheep IgG coupled to peroxidase
was purchased from Southern Biotechnology Associates Inc. (Birmingham, AL). L-αphosphatidylserine (PS) and L-α-phosphatidylcholine (PC) were obtained from Avanti
Polar Lipids (Alabaster, AL). Chemiluminescent reagent ECL+ and Heparin–Sepharose
were obtained from AmershamPharmacia Biotech Inc. (Piscataway, NJ).

Normal

reference plasma and the chromogenic substrate H-D-Hexahydrotyrosol-alanyl-arginyl-pnitroanilide diacetate (Spectrozyme-TH) were purchased from American Diagnostica Inc.
(Greenwich, CT).

RecombiPlasTin used in the clotting assays was purchased from

Instrumentation Laboratory Company (Lexington, MA). The reversible fluorescent αthrombin inhibitor dansylarginine-N- (3-ethyl-1,5-pentanediyl) amide (DAPA), human αthrombin, human prothrombin and active-site blocked human meizothrombin (obtained
following digestion of prothrombin with the purified component from the venom of the
snake Echis Carinatus as described (23), FPR-meizothrombin) were purchased from
Haematologic Technologies Inc. (Essex Junction, VT). Human factor Xa was from
Enzyme Research Laboratories (South Bend, IN). Human factor V cDNA was obtained
from American Type Tissue Collection (ATCC# 40515 pMT2-V, Manassas, VA). All
restriction enzymes were obtained from New England Biolabs (Beverly, MA).

All

molecular biology and tissue culture reagents, specific primers, and medium were
purchased from Gibco, Invitrogen Corp. (Grand Island, NY) or as indicated.
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Recombinant wild type prothrombin, prothrombin rMZ-II that has only one cleavage site
for factor Xa (i.e. Arg320) and prothrombin rP2-II that has only one cleavage site for
factor Xa (i.e. Arg271) were prepared and purified as previously described (24) and
provided by Dr. Michael Nesheim (Queen’s University, Kingston, Ontario Canada).
Human factor V monoclonal antibodies (αHFVHC17 and αHFVLC9) used for
immunoblotting experiments and monoclonal antibody αHFV1 coupled to Sepharose
used to purify plasma and recombinant factor V molecules were provided by Dr. Kenneth
G. Mann (Department of Biochemistry, University of Vermont, Burlington, VT).
Mutagenesis and Transient Expression of Recombinant Factor V Molecules.
The factor V cDNA consists of a 6,909 bp long fragment inserted into the pMT2
mammalian expression vector at the SalI site. Mutant factor V molecules consisting of
point mutations and various deletions to the COOH-terminus of the heavy chain were
synthesized using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA, USA) according to the manufacturer’s instructions. The mutagenic primers used for
the deletions were 58-base pair primers on the sense and antisense strands of the
recombinant

factor

V

molecule.

The

primers

for

factor

V5K

were

5’-

TGAGGCTGAAATTCAGGGATGTTAAATGTATCCCAAAGAAGAAGAAAAAGTC
ATATGAGATTTTTGAACCTCCAGAATC-3’

(sense)

and

5’-

GATTCTGGAGGTTCAAAAATCTCATATGACTTTTTCTTCTTCTTTGGGATACAT
TTAACATCCCTGAATTTCAGCCTCA-3’ (antisense). Primers for factor V659-663 were,
5’AGGCTGAAATTCAGGGATGTTAAATGTATCCCATCATATGAGATTTTTGAACC
TC-3’

(sense),

and
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5’-

GAGGTTCAAAAATCTCATATGATGGGATACATTTAACATCCCTGAATTTCAGC
CT-3’

(antisense).

Primers

for

V5A

factor

were

5’-

GCTGAAATTCAGGGATATTAAATGTATCCCAGCGGCGGCGGCGGCGTCATAT
GAGATTTTTGAACCTCCAGA-3’

(sense),

5’-

TCTGGAGGTTCAAAAATCTCATATGACGCCGCCGCCGCCGCTGGGATACATTT
AACATCCCTGAATTTCAGC-3’ (antisense), respectively. The mutagenized primers
were transformed into competent E.coli cells and positive ampicillin-resistant clones
were selected to screen for mutants. Wild-type factor V and mutant factor V clones were
cultured and isolated using the PureLink Quick Plasmid miniprep Kit (Invitrogen,
Carlsbad, CA). The incorporation of the mutations in the cDNA was verified by DNA
sequence analysis, using factor V-specific primers. Transfection and harvesting of the
media was performed as described in detail by our laboratory (14, 25). All media
containing the recombinant factor V molecules were concentrated using the Vivaflow 50
Complete System (Vivascience AG, Hannover, Germany) according to manufacturer’s
instructions. All recombinant factor V molecules were purified according to the detailed
protocol previously described by our laboratory (25).

The concentration of the

recombinant proteins was determined by ELISA as previously described (14).

The

activity and integrity of the recombinant molecules was verified before and after
activation with thrombin by clotting assays using factor V-deficient plasma and by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by
Western Blotting using both monoclonal and polyclonal antibodies. In some instances
factor Va fragments were also visualized following staining with silver.
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Gel Electrophoresis and Western Blotting. SDS-PAGE analyses of recombinant
factor V molecules were performed using 4-12% gradient gels according to the method of
Laemmli (26).

Proteins were transferred to polyvinylidene difluoride (PVDF)

membranes according to the method described by Towbin et al.(27). After transfer to
PVDF, factor V heavy and light chain(s) were detected using the appropriate monoclonal
and polyclonal antibodies (28, 29). Immunoreactive fragments were visualized with
chemiluminescence. In several instances recombinant factor V and factor Va fragments
obtained following activation of the procofactor with thrombin were visualized following
staining of the gels with silver as described (30).
Analysis of Prothrombin or Recombinant Mutant Prothrombin Activation and
FPR-Meizothrombin Cleavage at Arg271 by Gel Electrophoresis. Prothrombin or
recombinant mutant prothrombin molecules (1.4μM) were incubated with PCPS vesicles
(20μM), DAPA (50μM), and factor Va (10-20nM) in the presence of 5 mM Ca2+ in 20
mM Tris, 0.15 M NaCl, pH 7.4. The reaction was initiated upon addition of factor Xa
(0.5-1 nM) at room temperature over the time course indicated in the legend to the
figures. Aliquots (50 μl ) from the reaction were removed at selected time intervals (as
indicated in the legend to the figures), diluted into 2 volumes of 0.2 M glacial acetic acid
and concentrated using a Centrivap concentrator attached to a Centrivap cold trap
(Labconco, Kansas City, MO). The dried samples were dissolved in 0.1 M Tris-base, pH
6.8, 1% SDS, 1% β-mercaptoethanol, heated for exactly 75s at 90°C, mixed, and
subjected to SDS-PAGE using 9.5% gels prepared according to the method of Laemmli
(26); 6μg of protein per lane was applied. FPR-meizothrombin cleavage at Arg271 was
assessed in a similar manner using 12% SDS-PAGE. Protein bands were visualized
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following staining with Coomassie Brilliant Blue R and destained by diffusion in a
methanol/acetic acid/water solution.
Scanning densitometry of SDS-PAGE and calculation of the rate of prothrombin
consumption. Scanning densitometry of the gels was performed as described (31).
Briefly, the stained gels were scanned and imported into the software UN-SCAN-IT gel
(Silk Scientific, Orem UT). The numbers were normalized to the initial concentration of
prothrombin (1.4 μM) and adjusted for the capability of each fragment to be stained by
Coomassie as described (32). Following scanning densitometry, the data representing
prothrombin consumption as a function of time (sec) were subsequently plotted using
nonlinear regression analysis and the equation representing a first-order exponential
decay using the software Prizm (GraphPad, San Diego, CA). The apparent first-order
rate constant, k (s-1), obtained directly from the fitted data was divided by the molar
concentration of factor Xa used in each experiment.

The number obtained was

subsequently multiplied by the starting concentration of prothrombin. The final numbers
reported throughout the manuscript characterizing the effect of the mutations on plasmaderived prothrombin consumption by prothrombinase assembled with various
recombinant factor Va molecules, represent moles of prothrombin consumed per mole of
factor Xa per second for a given experiment. The consumption rates reported in the
manuscript are representative of experiments performed at least in triplicate using 2-4
different preparations of recombinant proteins. All constants reported in Tables 3.II and
3.III were extracted directly from the fitted data. The tables also report the standard
deviation for each measurement. In the legend to the figures we are also providing the
goodness of the fit to the equation representing a first-order exponential decay (R2).
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Measurement of Rates of Thrombin Formation in a Prothrombinase Assay. All
factor V molecules, both recombinant and plasma, were activated with human αthrombin as described (33).

The assay verifying the activity of the recombinant

molecules was conducted as described by measuring thrombin formation by the change in
the absorbance of a chromogenic substrate at 405 nm (Spectrozyme-TH) monitored with
a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA) (14, 20).
Absorbance at 405 nm was compared with a standard curve prepared daily using purified
thrombin (0-50 nM).
For the functional calculation of the apparent dissociation constants (KDapp) between
the recombinant factor Va molecules and factor Xa, experiments were performed in the
presence of a limited concentration of factor Xa (15 pM) and varying concentrations of
factor Va (between 30 pM and 5 nM). Throughout all experiments the assumption was
n =moles of factor Xa bound/mole of factor Va at saturation; throughout this study n = 1;
the stoichiometry of the factor Va-factor Xa interaction was fixed at 1. The initial rate of
thrombin formation was calculated, and the data were analyzed and plotted using
nonlinear regression analysis and the software Prizm (Graphpad, GraphPad, San Diego,
CA) according to the one binding site model. Dissociation constants reported in the
manuscript were extracted directly from the fitted data. In the legend to the figures we
are also providing the goodness of the fit to the one binding site model (R2).
The assay using purified reagents and verifying the cofactor activity of the
recombinant factor V molecules for prothrombin activation was conducted under
conditions where all factor Xa was saturated with factor Va, as described by measuring
α-thrombin formation by the change in the absorbance of a chromogenic substrate at 405
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nm (Spectrozyme-TH, 0.4 mM) (14).

All factor V molecules were activated with

thrombin as described (19, 20). Knowing the KDapp of each factor Va species for factor
Xa, the amount necessary to saturate factor Xa was calculated using the quadratic
equation described in the literature (34) before each experiment. The absorbance was
monitored with a Thermomax microplate reader and compared to a α-thrombin standard
prepared daily using purified plasma-derived α-thrombin. The data were analyzed and
plotted using nonlinear regression analysis and the software Prizm according to the Henri
Michaelis-Menten equation. Kinetic constants provided throughout the manuscript were
extracted directly from the fitted data. In addition, in the legend to the figures we are
reporting the goodness of the fit to the Henri Michaelis-Menten equation (R2).
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3.4 Results
Transient Expression and Activation of Recombinant Factor V Molecules. In
order to assess the importance of amino acid region 659-663 from the heavy chain of
factor Va, we constructed three mutant molecules. We prepared recombinant factor VΔ659, factor V5A, and factor V5K (Fig.3.1).

663

Recombinant factor VWT and the mutant

molecules were expressed in mammalian cells and purified by immunoaffinity
chromatography as previously described in detail by our laboratory (25).

All

recombinant mutant molecules were activated with thrombin. Figure 3.3 illustrates a
typical quality control procedure performed prior to all experiments. Panels A-C show
the subunit composition the recombinant molecules prior and after activation by
thrombin. SDS-PAGE analyses followed by immunoblotting with specific monoclonal
antibodies to the heavy and light chain of the cofactor demonstrate that the mutant
recombinant proteins are intact and composed of heavy and light chains that migrated in
accord with their expected molecular weights (panel D). In addition, experiments using a
polyclonal antibody to factor V demonstrate that all factor V molecules were fully
activated prior to use (not shown).
The recombinant molecules were assessed for their clotting activity in a two-stage
clotting assay. Thrombin activation of factor VWT resulted in a cofactor with similar
clotting activity as the plasma-derived molecule (Table 3.I). Under similar experimental
conditions factor VaΔ659-663, factor Va5K and factor V5A displayed 3.5-, 10-, and 24-fold
less clotting activities respectively compared to the clotting activity of factor VaWT (Table
3.I). These data demonstrate that amino acid region 659-663 is important for expression
of optimal factor Va clotting activity.
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Kinetic Analyses of Recombinant Factor Va Molecules. We next examined the
capability of the recombinant factor Va molecules to bind factor Xa and to assemble in
prothrombinase using an assay employing purified reagents and a chromogenic substrate
to probe for thrombin generation. The assay was performed under conditions of limiting
factor Xa concentrations while varying the concentration of recombinant factor Va
molecules. Figure 3.4A and Table 3.I show the results of the kinetic studies. The data
demonstrate that under the experimental conditions used, factor VaWT has similar affinity
for the enzyme, factor Xa, as its plasma counterpart. Likewise, the three recombinant
mutant factor Va molecules have similar affinities for plasma-derived factor Xa which
are indistinguishable from the affinity of factor VaWT for factor Xa. These results are in
complete accord with our recent findings (18) and demonstrate that the acidic hirudin-like
amino acid regions from the COOH-terminal of the heavy chain of factor Va do not
participate in the interaction of the cofactor with plasma-derived factor Xa (Table 3.I).
We subsequently evaluated the effect of the mutations on the Km and kcat of
prothrombinase. The raw data are displayed in Figure 3.4B, the values of the kcat and Km
for each set of titration are reported in Table 3.I, and a comparison of the second order
rate constants is displayed in figure 3.4C. Since we wanted to prevent the possibility that
differences between prothrombinase assembled with factor VaWT and prothrombinase
assembled with the two recombinant mutant factor Va molecules may be attributed to
subtle differences in the KDapp of factor Va for factor Xa, which would result in a lesser
amount of prothrombinase formed, all experiments shown in figure 3.4B were conducted
under conditions where factor Xa was saturated with factor Va. Calculations were
performed using the dissociation constants of all recombinant molecules for factor Xa
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shown in Table 3.I as extensively described (34). Under the experimental conditions
employed the mutations had no significant effect on the Km of the reaction, while the
catalytic efficiencies of prothrombinase assembled with the three mutant recombinant
cofactor molecules were decreased compared to the catalytic efficiency of
prothrombinase assembled with factor VaWT (Fig. 3.4B, Table 3.I). The data show that
prothrombinase assembled with factor Va5K or factor Va5A have approximately 50%
reduced catalytic efficiency when compared to the catalytic efficiency of factor VaWT,
while factor VaΔ659-663 has a 40% reduced catalytic efficiency, compared to the value
obtained for prothrombinase assembled with the wild type cofactor. Comparison of the
second-order rate constant between prothrombinase assembled with the recombinant
mutant molecules (kcat/Km) with the second-order rate constant obtained with
prothrombinase assembled with the wild type or the plasma-derived cofactor
demonstrates that the turnover number for prothrombinase assembled with the mutant
molecules is 40-50% reduced (Fig.3.4C). The inability of prothrombinase assembled
with the mutant cofactor molecules to function optimally coupled to the lack of effect of
the mutations on the dissociation constant of the recombinant mutant cofactor molecules
for plasma factor Xa, can be explained by the inability of factor Xa to efficiently convert
prothrombin to thrombin because of diminished productive collisions between the
enzyme and prothrombin. Overall, the data demonstrate that amino acid region 659-663
of factor Va has an important regulatory role during prothrombin activation by factor Xa
within prothrombinase.
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Figure 3.3. Electrophoretic analyses of wild type factor V and recombinant factor V
WT

5K

Δ659-663

5A

molecules. Factor V , factor V
, factor V , and factor V were activated with
thrombin as described in the “Experimental Procedures” section and analyzed by SDSPAGE followed by staining with silver (panels A-C). Lane 1, factor V prior to activation
by thrombin; lane 2, recombinant molecules following incubation with thrombin. Panel
D, following SDS-PAGE and transfer to a PVDF membrane, immunoreactive fragments
were detected with monoclonal antibodies αHFVa 17 (recognizing an epitope on the
HC

heavy chain of the cofactor between amino acid residues 307-506) and αHFVa 9
HC

(recognizing the light chain). At the right of all panels the positions of factor V as well as
of the heavy/light chains of factor Va are shown.
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Figure 3.4A. Factor Va titrations to determine the affinity of the recombinant factor
Va molecules for factor Xa. Thrombin generation experiments were carried out as described
WT

5K

Δ659-663

5A

, factor V , and factor V
under “Experimental Procedures”. Factor V , factor V
were activated by thrombin and assayed for factor Xa binding as described in the
“Experimental Procedures”. The solid lines represent a nonlinear regression fit of the data
using Prizm GraphPad software according to the equation of a one binding site (hyperbola)
model. Prothrombinase complex was assembled with varying concentrations of
WT

recombinant factor Va
2

5A

2

(filled squares, R =0.98), factor Va

Δ659-663

(filled circles,

5K

2

R =0.96), factor Va (filled diamonds, R =0.99) and factor Va (filled inverse triangles,
2

R =0.97). The dissociation constants reported in Table 3.1 were extracted directly from
the fitted data.
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Figure 3.4B. Prothrombin titration to determine the kinetic parameters of
prothrombinase assembled with various recombinant factor Va species. Thrombin
generation experiments were carried out as described under “Experimental Procedures”
by varying the substrate concentration (25 nM to 4 μM) with factor Xa saturated with
WT

each of the recombinant factor Va species. Factor V
5K

PLASMA

, factor V

Δ659-663

, factor V

,

5A

factor V , and factor V were activated with thrombin as described in the
“Experimental Procedures” section. The solid lines represent the nonlinear regression fit
of the data using Prizm GraphPad software according to the Henri Michaelis-Menten
WT

equation. Prothrombinase was assembled with recombinant factor Va
PLASMA

2

R =0.99), factor Va

5K

2

R =0.94), factor Va

2

(filled triangles, R =0.97), factor Va

(filled circles,

(filled inverse triangles, R =0.97), and factor Va
WT

diamonds, R =0.98). The data with factor Va
factor V

(filled squares,

2

2

5K

Δ659-663

PLASMA

, factor Va

5A

(filled

Δ659-663

, factor Va

, and

show the average results obtained from at least three different titrations with
5A

three different preparations of purified proteins. The data with factor Va are
representative of two titrations obtained in duplicate using two different preparations of
recombinant protein. Kinetic constants reported in the text and in Table 3.I were
extracted directly from fitted data.
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Figure 3.4C. Determination of the kinetic parameters of prothrombinase assembled
with the various recombinant factor Va species. Second-order rate constants for
-1

-1

prothrombinase assembled with all cofactor molecules (M • s ).
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Table 3.I
Functional properties of various factor Va molecules
Factor Va
Species

KDapp
(nM)b

kcat
(min-1)c

Km
(μM)c

Factor VaPLASMA

Clotting
Activity
(U/mg)a
3124 ± 413

0.70 ± 0.1

2287 ± 87

0.3 ± 0.04

Factor VaWTa

2926 ± 320

0.81 ± 0.1

2397 ± 37

0.2 ± 0.01

Factor VaΔ659-663

823 ± 180

1.0 ± 0.2

1493 ± 58

0.2 ± 0.03

Factor Va5K

275 ± 92

0.8 ± 0.2

1135 ± 36

0.3 ± 0.03

Factor Va5A

120 ± 30

0.8 ± 0.1

1074 ± 51

0.3 ± 0.05

Table 3.I aTwo-stage clotting assays of recombinant factor V molecules was performed
as described in the “Experimental Procedures” section.
b
Apparent dissociation constants of recombinant factor Va for plasma-derived factor Xa
(KDapp) were determined as described in the “Experimental Procedures” section at
limiting factor Xa concentrations (15 pM) according to the binding model assuming one
binding site using the software Prizm. Dissociation constants were derived directly from
the fitted data.
c
The Km and kcat of prothrombinase assembled with saturating concentrations of
recombinant factor Va molecules were determined as described in the “Experimental
Procedures” section according to the Michaelis-Menten equation using the software
Prizm. Kinetic constants were derived directly from the fitted data.
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The findings obtained thus far suggest that prothrombin cleavage and activation by
prothrombinase assembled with the recombinant mutant molecules is deficient. These
data indicate that the rate of one or both of the two prothrombin activation cleavages are
impaired when prothrombinase is assembled with a cofactor molecule mutated at the 659663 amino acid region of the heavy chain.
To better understand the deficiency in prothrombin cleavage and activation by
prothrombinase assembled with the recombinant mutant cofactor molecules, we have
studied prothrombin activation by gel electrophoresis. The results demonstrate a delay in
prothrombin activation by prothrombinase assembled with either VaΔ659-663, factor Va5K,
or factor Va5A as compared to the activation of prothrombin by prothrombinase
assembled with either factor VaPLASMA or factor VaWT (Fig. 3.5, panels A-E). Scanning
densitometry of the gels shown in figure 3.5 demonstrated a 3- and 7-fold delay in
prothrombin consumption by prothrombinase assembled with factor VaΔ659-663 and factor
Va5K respectively, as compared to the consumption of prothrombin assembled with factor
VaWT(Fig.3.6 and Table 3.II). Interestingly, prothrombin consumption by prothrombinase
assembled with factor Va5A was most severely impaired and no meizothrombin was
visible during the activation process (Figs 3.5E). In addition, when prothrombin is
activated by prothrombinase assembled with either factor VaΔ659-663 or factor Va5K, there
is persistence (lingering) of meizothrombin throughout the activation process (Figs 3.5C
and 3.5D).

Scanning densitometry demonstrated that a peak for meizothrombin is

observed at 120 sec when prothrombin is activated by prothrombinase assembled with
factor VaWT, while a peak for meizothrombin is detected at 200 sec and 360 sec when
prothrombin is activated by prothrombinase assembled with either factor VaΔ659-663 or
99
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Figure 3.5. Analysis of the activation of plasma-derived prothrombin by
prothrombinase assembled with various mutant factor Va molecules. Plasma-derived
prothrombin (1.4 μM) was incubated in different mixtures with PCPS vesicles (20 μM),
WT

and prothrombinase assembled with either factor Va (panel A) or factor Va
(panel B) as described in the “Experimental Procedures” section. Panel C,
prothrombinase assembled with factor Va

PLASMA

Δ659-663

; panel D, prothrombinase assembled

5K

5A

with factor Va ; panel E, prothrombinase assembled with factor Va . The reactions
were started by the addition of factor Xa. At selected time intervals aliquots of the
reaction mixtures were withdrawn and treated as described in the “Experimental
Procedures” section. M represents the lane with the molecular weight markers (from top
to bottom): M 98,000, M 64,000, M 50,000, M 36,000. Lanes 1-19 represent samples
r

r

r

r

from the reaction mixture before (0 min) the addition of factor Xa and 20 sec, 40 sec, 60
sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec, 220 sec, 240 sec, 5 min,
6 min, 10 min, 20 min, 30 min, and 60 min respectively following the addition of factor
Xa.
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Figure 3.6. Analysis of prothrombin consumption by prothrombinase assembled
with recombinant factor Va molecules. The gels shown in figure 3.5 were scanned and
prothrombin consumption was recorded as described in the “Experimental Procedures”
section. Following scanning densitometry, the numbers were normalized to the initial
concentration of prothrombin (1.4 μM). The data representing prothrombin consumption
(μM) as a function of time (sec) were subsequently plotted using non-linear regression
analysis according to the equation representing a first-order exponential decay using the
software Prizm (GraphPad, San Diego, CA). Prothrombinase was assembled with
WT

recombinant factor Va
2

Δ659-663

2

5A

R =0.98), factor Va

2

(filled triangles, R =0.98), factor Va
2

PLASMA
5K

(filled squares, R =0.99), factor Va

(filled circles,

(open squares,

R =0.93), and factor Va (open inverse triangles, the data were not a good fit to a first
order exponential decay model, see Table 3.2). The apparent first-order rate constant, k
-1

(s ), obtained directly from the fitted data was divided by the molar concentration of
factor Xa used in each experiment. The number obtained was subsequently multiplied by
the starting concentration of prothrombin. The resulting numbers representing
prothrombin consumption are reported in Table 3.II.
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Table 3.II

Rate of activation of native plasma-derived prothrombin and recombinant mutant
rMZ-II in the presence of prothrombinase assembled with various recombinant
factor Va species

Enzyme

Membrane-bound
factor Xa alone
Prothrombinase
assembled with factor
VaPLASMA
Prothrombinase with
factor VaWT
Prothrombinase with
factor VaΔ659-663
Prothrombinase with
factor Va5K
Prothrombinase with
factor Va5A

Plasma-derived
Prothrombin* (Initial
cleavage at Arg320)
(moles consumed • sec-1 •
mole factor Xa-1)
--

rMZ-II*
(Cleavage at Arg320)
(moles consumed • sec-1 • mole
factor Xa-1)
0.023 ± 0.017

19 ± 1.5

14.0 ± 0.8

21.8 ± 1.9

11.2 ± 1.1

7.7 ± 0.5

6.4 ± 0.6

3.3 ± 0.9

2.8 ± 0.8

NFa

NSCb

Table 3.II. The rates of plasma-derived prothrombin and recombinant mutant
prothrombin rMZ-II consumption were obtained following scanning densitometry of gels
shown in Figs.3.5 and 3.7 respectively. The final rate of prothrombin consumption in the
presence of prothrombinase assembled with various factor Va species, was extracted
following plotting of the data according to the equation representing a first-order
exponential decay as described in the “Experimental Procedures” section (Figs.3.6 and
3.9). The apparent first-order rate constants were obtained directly from the fitted data.
a
NF, no fit; the data could not be fitted to a first-order exponential decay (R2 = 0.0049).
The concentration of plasma-derived prothrombin varied from 1400 nM at time 0 to 200
nM following 1h incubation with prothrombinase assembled with factor Va5A.
b
NSC, not significant consumption. The concentration of rMZ-II varied from 1400 nM at
time 0 to 1260 nM following 2h incubation with prothrombinase assembled with factor
Va5A
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factor Va5K respectively. It is important to note, that in the latter case the detrimental
effect of the mutations is more pronounced on prothrombin activation than when amino
acid sequence 659-663 is deleted. However, mutating all amino acids from this region to
alanine appears to abolish the capability of factor Xa within prothrombinase for cleavage
of prothrombin at Arg320. These data are in complete accord with the data obtained in the
clotting assays and the combined data suggest that both prothrombin activation cleavages
(Arg320 and Arg271) appear to be affected to various degrees when prothrombinase is
assembled with factor VaΔ659-663, factor Va5K, or factor Va5A

However, because

meizothrombin lingers throughout the activation process, it appears that the rate of
cleavage of prothrombin at Arg271 is considerably more affected by a deletion of the 659663 amino acid region or a D→K substitution, than the rate of cleavage of prothrombin at
Arg320. In contrast, the D→A substitution in the hirudin-like acidic 659-663 region
appears to be equally detrimental to prothrombinase for cleavage of prothrombin at either
Arg320 or Arg271. Overall, the data demonstrate that 1) amino acid region 659-663 is
important for optimum activity of prothrombinase and 2) the nature of the mutations in
this region has an impact on the pathway and rate of prothrombin activation by
prothrombinase.
Activation of Recombinant Mutant Prothrombin by Prothrombinase Assembled
with Mutant Factor Va molecules. The data obtained thus far studying plasma-derived
prothrombin activation by prothrombinase assembled with the mutant cofactor molecules,
demonstrate that 1) meizothrombin lingers throughout the time course, 2) appearance of
the B-chain of thrombin is also delayed when prothrombin is activated by prothrombinase
assembled with two of the three mutant cofactor molecules; and 3) initial cleavage of
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prothrombin by prothrombinase assembled with factor Va5A is severely impaired. In
order to verify which cleavage in prothrombin is specifically affected by the
modifications in the 659-663 amino acid region of factor Va heavy chain, we first used
prothrombin molecules that cannot be cleaved at either Arg271 such as rMZ-II (Fig.3.7) or
at Arg320 (rP-II, Fig.3.8) (24).
The data demonstrate that there is a significant difference between the rates of
activation of rMZ-II by prothrombinase assembled with factor VaΔ659-663, factor Va5K, or
factor Va5A as compared to rMZ-II activated by prothrombinase made with factor VaWT
or factor VaPLASMA (Fig.3.7). Scanning densitometry of the gels shown in figure 3.7
demonstrate that cleavage at Arg320 of rMZ-II is delayed by ~2-fold when
prothrombinase is assembled with factor VaΔ659-663 and 4-fold when prothrombinase is
assembled with factor Va5K compared to cleavage of the recombinant mutant
prothrombin molecule by prothrombinase assembled with factor VaWT (Table 3.II, and
Fig.3.9). In contrast, no significant prothrombin consumption was observed when rMZ-II
was incubated with prothrombinase assembled with factor Va5A (Fig.3.7)

The data

confirm our overall findings with plasma-derived prothrombin and demonstrate that
prothrombinase-mediated cleavage at Arg320 in prothrombin is affected by the
modifications/deletion of amino acids 659-663 from the COOH-terminal portion of factor
Va heavy chain.
The data shown in figures 3.8 and 3.9, and in Table 3.III demonstrate that the rate of
cleavage of rP2-II at Arg271 by prothrombinase assembled with factor VaΔ659-663, factor
Va5K, or factor Va5A is undetectable compared to the rate of cleavage of rP2-II at Arg271
by prothrombinase assembled with either factor VaWT or factor VaPLASMA. In fact, these
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mutations in factor Va heavy chain practically abolish the capability of prothrombinase
assembled with any of the mutant cofactor molecules to cleave rP2-II at Arg271. Overall,
the data shown in figures 3.5-3.9 demonstrate that mutations in the acidic amino acid
segment 659-663 differentially affect the rate of the two activating cleavage sites of
prothrombin by prothrombinase. These data demonstrate that this portion of factor Va
heavy chain controls the catalytic efficiency of factor Xa within the enzymatic complex.
Activation of FPR-Meizothrombin by Prothrombinase Assembled with Mutant
Factor Va molecules. Analysis of the results obtained thus far with plasma-derived and
recombinant prothrombin suggests that activation of prothrombin by prothrombinase
assembled with factor VaΔ659-663, factor Va5K, and factor Va5A is severely impaired
compared to cleavage of the recombinant molecule by prothrombinase assembled with
factor VaWT because of delayed cleavage at both Arg320 and Arg271 resulting in both slow
prothrombin consumption and less conversion of meizothrombin to thrombin. It has been
shown that a change in conformation of meizothrombin is associated with cleavage of
prothrombin at Arg320 (35). To ascertain the effect of the mutations of the factor Va
heavy chain on the cleavage of prothrombin at Arg271 following the transition that occurs
after cleavage at Arg320, we compared the rate of cleavage of FPR-meizothrombin by
prothrombinase assembled with either factor VaWT or the recombinant mutant cofactor
molecules (Fig.3.10). The data demonstrate a delay for cleavage of FPR-meizothrombin
at Arg271 by prothrombinase assembled with factor VaΔ659-663 (panel B), factor Va5K
(panel C), or factor Va5A (panel D) as compared to the same reaction catalyzed by
prothrombinase assembled with factor VaWT (panel A).

Quantitative scanning

densitometry of fragment 1•2-A present on the gels shown in figure 3.10, demonstrated a
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~2-fold delay in cleavage of FPR-meizothrombin at Arg271 by prothrombinase assembled
with all mutant cofactor molecules, compared to cleavage at Arg271 by prothrombinase
assembled with factor VaWT (Fig.3.11, Table 3.III). However, the rates for cleavage of
FPR-meizothrombin at Arg271 are 2-fold faster than the rate of cleavage of FPRmeizothrombin by factor Xa alone. Thus, deletion or substitutions of amino acid residues
within region 659-663 has a similar effect on prothrombinase, namely, significantly
impedes acceleration of the rate of cleavage at Arg271 of meizothrombin attributed to the
interaction of factor Va with factor Xa (3, 36). These data are in complete agreement
with all the findings presented herein and overall our data demonstrate that amino acid
sequence 659DDDED663 from the factor Va heavy chain is indispensable for optimal rates
of thrombin formation during activation of prothrombin by prothrombinase.

108

Figure 3.7. Electrophoretic analyses of the activation of rMZ-II by prothrombinase
assembled with mutant factor Va molecules. rMZ-II was incubated in different
mixtures with PCPS vesicles, DAPA, and various factor Va molecules. The reaction was
started by the addition of factor Xa and the samples were treated as detailed in the
“Experimental Procedures” section. The gels were scanned and quantified as detailed
under “Experimental Procedures”. Lanes 1-9, represent samples of the reaction mixture
following incubation of prothrombinase with rMZ-II, before (lane 1), or following 1min,
3min, 5min, 10min, 20min, 45min, 60min, and 120min incubation with factor Xa
WT

respectively; Panel A, prothrombinase assembled with factor Va ; panel B
prothrombinase assembled with plasma-derived factor Va; panel C, prothrombinase
assembled with factor Va

5K

Δ659-663

; panel D, prothrombinase assembled with factor Va ;
5A

panel E, prothrombinase assembled with factor Va ; panel F, is a schematic of the
recombinant prothrombin molecule used (rMZ-II). This molecule is a triple mutant with
320

only one cleavage site for prothrombinase remaining at Arg . Positions of prothrombinderived fragments are indicated at right as detailed in the legend to figure 3.5. The factor
Va species used for the reconstitution of prothrombinase are shown under each panel.
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Figure 3.8. Electrophoretic analyses of the activation of rP2-II by prothrombinase
assembled with mutant factor Va molecules. rP2-II was incubated in different mixtures
with PCPS vesicles, DAPA, and various factor Va molecules. The reaction was started by
the addition of factor Xa and the samples were treated as detailed in the “Experimental
Procedures” section. The gels were scanned and quantified as detailed under
“Experimental Procedures”. Lanes 1-9, represent samples of the reaction mixture
following incubation of prothrombinase with rP2-II, before (lane 1), or following 1min,
3min, 5min, 10min, 20min, 45min, 60min, and 120min incubation with factor Xa
WT

respectively; Panel A, prothrombinase assembled with factor Va ; panel B
prothrombinase assembled with plasma-derived factor Va; panel C, prothrombinase
assembled with factor Va

5K

Δ659-663

; panel D, prothrombinase assembled with factor Va ;
5A

panel E, prothrombinase assembled with factor Va ; panel F, is a schematic of the
recombinant prothrombin molecule used (rP2-II). This molecule is a triple mutant with
271

only one cleavage site for prothrombinase remaining at Arg . Positions of prothrombinderived fragments are indicated at right as detailed in the legend to figure 3.5. The factor
Va species used for the reconstitution of prothrombinase are shown under each panel.
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Figure 3.9. Analysis of recombinant prothrombin consumption by prothrombinase
assembled with recombinant factor Va molecules. The gels shown in figures 3.7 and
3.8 were scanned and prothrombin consumption was recorded as described in the
“Experimental Procedures” section. Following scanning densitometry, the data
representing recombinant mutant prothrombin consumption as a function of time (sec)
were plotted using non-linear regression analysis according to the equation representing a
first-order exponential decay using the software Prizm (GraphPad, San Diego, CA) as
described in the legend to figure 6. Prothrombinase was assembled with recombinant
factor Va

WT

(filled triangles), factor Va
5K

squares), factor Va

PLASMA

(filled circles), factor Va

(open squares), and factor Va

5A

Δ659-663

(filled

(open inverse triangles). The

-1

apparent first-order rate constant, k (s ) was obtained directly from the fitted data. The
resulting numbers representing recombinant mutant prothrombin consumption are
reported in Table 3.2 and table 3.3. Panel A; shows the data obtained following cleavage
WT

of rMZ-II: factor Va
5K

PLASMA

2

, R =0.99, factor Va

2

2

, R =0.99, factor Va

Δ659-663

2

, R =0.99,

and factor Va , R =0.94. Panel B; shows the data obtained following cleavage of rP2-II:
WT

factor Va

2

PLASMA

, R =0.99, factor Va

2

, R =0.98.
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Figure 3.10. Gel electrophoresis analyses for cleavage of FPR-meizothrombin. FPRmeizothrombin (1.4 μM) was incubated in different mixtures with PCPS vesicles (20 μM)
and factor Va as described in the legend to figure 3.5. The reactions were started by the
addition of factor Xa and the samples were further treated, scanned and quantified as
WT

detailed in the “Experimental Procedures” section. Panel A, factor Va
Δ659-663

5K

; panel B, factor

5A

; panel C, factor Va , panel D, factor Va , M represents the lane with the
Va
molecular weight markers (from top to bottom): M 50,000, M 36,000, M 22,000. Lanes
r

r

r

1-19 represent samples from the reaction mixture before (0 min) the addition of factor Xa
and 20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec,
220 sec, 240 sec, 5 min, 6 min, 10 min, 20 min, 30 min, and 60 min respectively
following the addition of factor Xa. The prothrombin derived fragments are shown as
detailed in the legend to figure 3.5. The recombinant factor Va species used for the
reconstitution of prothrombinase are shown under each panel.
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Figure 3.11. Analysis of FPR-meizothrombin consumption by prothrombinase
assembled with recombinant factor Va molecules. The gels shown in figure 3.10 were
scanned and FPR-meizothrombin consumption was recorded as described in the
“Experimental Procedures” section. Following scanning densitometry, the data
representing prothrombin consumption as a function of time (sec) were plotted using nonlinear regression analysis according to the equation representing a first-order exponential
decay using the software Prizm (GraphPad, San Diego, CA) as described in the legend to
-1

figure 3.6. The apparent first-order rate constant, k (s ) was obtained directly from the
fitted data. Prothrombinase was assembled with recombinant factor Va
5K

Δ659-663

WT

(filled
5A

(filled squares), factor Va (open squares), and factor Va
triangles), factor Va
(open inverse triangles). The resulting numbers representing FPR-meizothrombin
consumption are reported in Table 3.III.

115

Table 3.III

Rates of activation of recombinant prothrombin rP2-II and plasma-derived FPRMeizothrombin in the presence of various recombinant factor Va species

Enzyme

rP2-II*

FPR-Meizothrombin*

(Cleavage at Arg271)

(Cleavage at Arg271)

(moles of rP2-II consumed •

(moles of fragment 1•2-A

sec-1 • mole factor Xa-1)

consumed • sec-1 • mole factor Xa1

)

Factor Xa alone

0.048 ± 0.013

13.5a

Prothrombinase

3.3 ± 0.4

42.6a

3.4 ± 0.5

52.2 ± 14

NSCb

23.5 ± 2.1

NSCc

20.1 ± 4.3

NSCd

26.1 ± 2.2

with factor
VaPLASMA
Prothrombinase
with factor
VaWT
Prothrombinase
with factor
VaΔ659-663
Prothrombinase
with factor Va5K
Prothrombinase
with factor Va5A
Table 3.3. *Rates of rP2-II consumption in the presence of wild-type or plasma factor Va
and recombinant mutant factor VaΔ659-663, factor Va5K and factor Va5A were measured
following scanning densitometry of gels shown in Fig.3.8. Calculation of the apparent
first-order rate constant was achieved as detailed in “Experimental Procedures”. The rate
of fragment 1•2-A consumption in the presence of prothrombinase assembled with factor
VaWT, factor VaΔ659-663, factor Va5K and factor Va5A was measured following scanning
densitometry of the gels shown in Fig.3.10 and calculation of the apparent first-order rate
constant as detailed in “Experimental Procedures”. The rates of rP2-II and fragment 1•2-
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A consumption were extracted from the fitted data (shown in Figs. 3.9 and 3.11
respectively).
a
From reference (18).
b
NSC, not significant consumption. The concentration of rP2-II varied from 1400 nM at
time 0 to 1250 nM following 2h min incubation with prothrombinase assembled with
factor VaΔ659-663.
c
NSC, not significant consumption. The concentration of rP2-II varied from 1400 nM at
time 0 to 1220 nM following 2h min incubation with prothrombinase assembled with
factor Va5K.
d
NSC, not significant consumption. The concentration of rP2-II varied from 1400 nM at
time 0 to 1100 nM following 2h min incubation with prothrombinase assembled with
factor Va5A.
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3.5 Discussion
Our data demonstrate that the acidic region 659-663 located at the COOHterminus of factor Va heavy chain is responsible for coordinated activation of
prothrombin by prothrombinase resulting in timely thrombin formation at the place of
vascular injury. To our knowledge, this is the first time that the role of this specific
amino acid region of the cofactor has ever been investigated. The data presented here,
assign an important physiological role to the acidic region 659-663 from the COOHterminus of factor Va heavy chain for efficient prothrombin activation. Namely, amino
acid sequence

659

DDDED663 regulates the rate of cleavage of prothrombin by

prothrombinase at Arg320 and Arg271. This acidic amino acid sequence together with
sequence

695

DYDYQ699 (18, 20, 21) are both located on the surface of the factor Va

molecule (37), and are conserved among species (Fig.3.2) attesting to their physiological
significance. Since both sequences have no effect on the direct interaction between factor
Va and factor Xa, our findings are consistent with the interpretation that these acidic
amino acid sequences contribute significantly to the macromolecular substrate
recognition of prothrombin by prothrombinase and demonstrate that factor Va indeed
regulates the activity of factor Xa within the enzymatic complex.
Proteolytic inactivation of factor Va by activated protein C (APC) following
cleavages at Arg506, Arg306, and Arg679 (38, 39) results in the arrest of the contribution of
the cofactor to the catalytic efficiency of factor Xa. Earlier data have demonstrated that
factor Xa and prothrombin protect the cofactor from APC inactivation (40-42).
Functional data obtained with plasma or natural and/or recombinant mutant factor Va
molecules have established that cleavages at Arg306 and Arg506 result in the dissociation
of the A2 domain of the cofactor from the rest of the molecule (37, 43-46). The A2
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domain of factor Va contains the major factor Xa binding domains (13, 14, 47, 48).
Thus, dissociation of the A2 domain from the rest of the molecule results in impaired
factor Xa-factor Va interaction. However, a specific role for cleavage at Arg679 has not
been yet determined and has been mystifying scientists since the initial identification of
the specific inactivating cleavage sites of the human cofactor approximately 15 years ago
(39). Our data demonstrate that the acidic hirudin-like sequences from the COOHterminal portion of the heavy chain of factor Va direct the rate of prothrombin activation
by factor Xa because they are part of a regulatory group of amino acids from the cofactor
controlling the rate of the two prothrombin activation cleavage sites. Our data put in the
context of the literature suggest that cleavage of the cofactor by APC at Arg679
destabilizes the structure of the COOH-terminus of the heavy chain of factor Va and
eliminates its regulatory role on the two prothrombin activation cleavages, resulting in
uncontrolled meizothrombin generation by the prothrombinase complex. This conclusion
is also strengthened by the fact that the acidic regions from the COOH-terminal region of
factor Va heavy chain together with the Arg679 APC-cleavage site are conserved among
species (Fig.3.2). Overall, the data strongly suggest that proteolytic inactivation of factor
Va by APC results in the inability of the cofactor to bind factor Xa and to provide a
productive regulatory interaction with prothrombin. Thus, our findings also offer for the
first time a logical explanation for the role of cleavage of factor Va by APC at Arg679.
Data obtained with plasma-derived prothrombin show delay in prothrombin
consumption when prothrombinase was assembled with factor VaΔ659-663, factor Va5K, or
factor Va5A, compared to plasma-derived prothrombin activation by prothrombinase
assembled with factor VaWT. Clotting assays using factor VaΔ659-663, factor Va5K, and
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factor Va5A showed a comparable decrease in clotting activity compared to the activity of
factor VaWT. Similarly, experiments using rMZ-II demonstrate that cleavage at Arg320
and rMZ-II consumption is delayed significantly when prothrombinase is assembled with
factor VaΔ659-663, factor Va5K, and factor Va5A, as compared to cleavage of rMZ-II by
prothrombinase assembled with factor VaWT. These data together with the data shown in
figures 3.8 and 3.10 demonstrating that elimination of the amino acid region 659-663 in
factor Va heavy chain or substitution of all amino acids from this region by either lysine
or alanine, result in the elimination of the acceleration of the rate of cleavage of rP2-II
and FPR-meizothrombin at Arg271 due to the interaction of factor Va with factor Xa.
These data suggest that lingering of meizothrombin during prothrombin activation by
prothrombinase assembled with the mutant cofactor molecules is the consequence of
delayed cleavage at and Arg271. However, we must note a differential effect of the
mutations on the two prothrombin activation cleavage sites. Thus, while prothrombinase
assembled with factor Va5A is severely impaired for initial cleavage at Arg320 of
prothrombin or rMZ-II as compared to cleavage of the two molecules by prothrombinase
assembled with either factor VaΔ659-663 or factor Va5K, prothrombinase assembled with
factor Va5A has similar activity for cleavage of either rP2-II or FPR-meizothrombin as
prothrombinase assembled with factor VaΔ659-663 or factor Va5K. Overall, our findings
convincingly demonstrate that prothrombinase assembled with factor VaΔ659-663 is a better
enzyme than prothrombinase assembled with factor Va5K, which in turn is a better
enzyme than prothrombinase assembled with factor Va5A for cleavage at Arg320. These
data strongly suggest a differential effect of the mutations within amino acid region 659663 of factor Va heavy chain on the rate of the two prothrombin activating cleavage sites.
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It is well established that cleavage of prothrombin at Arg271 has an important effect on
the progressive formation of the active site of thrombin (49, 50), and that meizothrombin
has higher amidolytic activity than thrombin towards several chromogenic substrates
usually employed to assess thrombin esterase activity (23, 51-53). In addition, it has
been demonstrated following analysis of the crystal structure of meizothrombin, that
ABE-II of meizothrombin has not yet been exposed, because it is covered by fragment 2
(54). This fact alone explains the poor clotting activity of meizothrombin since ABE-II is
part of the binding site of thrombin for fibrinogen and is required for optimal rate of
fibrin formation during blood clotting.

ABE-II is exposed following cleavage of

meizothrombin at Arg271 and release of fragment 2. However, the catalytic activity of
prothrombinase when assembled with the mutant cofactor molecules is only moderately
affected by the mutations, when the activity of factor Va is measured in an assay using a
chromogenic substrate to assess for thrombin activity (half to 1/3 of the values found with
prothrombinase assembled with the wild type cofactor). Indeed, the kcat and second order
rate constants of prothrombinase assembled with the mutant factor Va molecules are
approximately 50% of that of prothrombinase assembled with factor VaPLASMA or factor
VaWT. In contrast, the clotting activity of the mutant cofactor molecules is severely
impaired and gel electrophoresis experiments combined with densitometric analyses
reveal a significant delay in prothrombin activation with meizothrombin being more
stable throughout the activation process when prothrombinase is assembled with the
mutant molecules as compared to prothrombin activation by prothrombinase assembled
with either factor VaWT or factor VaPLASMA. The data demonstrate a delay in prothrombin
activation and thrombin generation because of impaired rates of cleavage at both Arg320
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and Arg271 with the rate of cleavage at Arg271 being affected the most, and with the
659

DDDED663→AAAAA substitution being the most detrimental to factor Va cofactor

activity.

The findings presented herein are entirely consistent with earlier findings

obtained with plasma-derived proteins (55-57), recent findings obtained with
recombinant proteins (58) and our data (18, 19). Explicitly, when prothrombinase is
assembled with a factor Va molecule possessing a heavy chain which is truncated at the
acidic hirudin-like COOH-terminal region, a discrepancy is observed between the activity
of factor Va measured by clotting assay as compared to the activity of the cofactor
measured in an assay using a chromogenic substrate to assess for thrombin activity. The
data provided herein and in our recent manuscript detailing the properties of factor VΔ680709

(18), explain these paradoxical findings. Because we have studied prothrombin, rMZ-

II, rP2-II, and FPR-meizothrombin activation by gel electrophoresis, we can conclude
that meizothrombin lingers throughout the activation of prothrombin by prothrombinase
assembled with the recombinant mutant molecules. The excess meizothrombin present in
the assays while having poor clotting activity can compensate for the lack of thrombin
activity because of its increased amidolytic activity towards chromogenic substrates (51,
52) that are usually employed to assess thrombin activity, thus creating the false
impression that the mutations have a minimal effect on prothrombinase activity. As a
consequence, and because factor Va is a cofactor molecule devoid of enzymatic activity,
when studying recombinant mutant factor Va molecules, drawing conclusions from
activity assays only, without visualizing the pathway to thrombin generation, would lead
to incorrect interpretations of the prothrombin intermediates formed and the rate of the
specific prothrombin activating cleavages. We therefore conclude that following the
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activity of various recombinant mutant factor Va molecules by clotting assays, gel
electrophoresis analyses, and assays using chromogenic substrates is by no means
redundant and prevents oversimplification that in turn might lead to flawed conclusions.
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CHAPTER IV
THE COFACTOR EFFECT OF AMINO ACIDS 695 AND 696 OF
FACTOR VA HEAVY CHAIN ON THE ENZYMATIC ACTIVITY OF
THE PROTHROMBINASE COMPLEX

4.1 Abstract
Blood coagulation is initiated after vascular injury, promoting formation of the
fibrin clot.

Without the proper regulation of this process, serious life threatening

conditions, such as DVT (deep vein thrombosis), can occur. The proteolytic conversion
of prothrombin to thrombin is catalyzed by the prothrombinase complex composed of the
enzyme, factor Xa (fXa), the cofactor, factor Va (fVa), assembled on a membrane surface
in the presence of Ca2+ [1]. The incorporation of fVa into the prothrombinase complex
results in a 300,000-fold increase in the catalytic efficiency of fXa for thrombin
generation. Prothrombinase activates prothrombin through initial cleavage at Arg320
followed by cleavage at Arg271 to yield human alpha-thrombin [2]. This pathway is
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responsible for the generation of a transient intermediate, meizothrombin, which is
enzymatically active with increased chromogenic substrate activity, but yields poor
clotting activity [3]. Factor Va is composed of heavy and light chains that play a crucial
role during thrombin formation. Portions of the fVa heavy chain have been found to act
as fXa binding sites and to interact with proexosite 1 (pro1) of prothrombin to increase
prothrombinase activity [4, 5]. It has been recently demonstrated that deletion of the
COOH-terminal region of the factor Va heavy chain causes accumulation of
meizothrombin due to delayed cleavage of prothrombin at Arg271 [3].

Site-directed

mutagenesis was performed to generate recombinant mutant molecules to identify the
specific amino acids of this terminal region that regulate cleavage. Mutants with the
695

DYDY698→ DFDY(fVaDFDY), KFDY(fVaKFDY), DEDE(fVaDEDE), DFDF(fVaDFDF)

substitutions were constructed. SDS-PAGE analyses of prothrombin activation time
courses revealed that the overall cleavage of prothrombin by prothrombinase assembled
with fVaKFDY and fVaDFDY was delayed, while fVaDEDE, and fVaDFDF had no significant
effects when compared to fVaWT. Two- stage clotting assays (PT times) revealed that
prothrombinase assembled with fVaKFDY had reduced clotting activity when compared to
fVaWT, while fVaDEDE, fVaDFDY, and fVaDFDF gave similar clotting results as fVaWT.
Determination of kcat values for prothrombinase assembled with the various recombinant
molecules revealed that fVaKFDY and fVaDFDY lead to an increase in the catalytic
efficiency of the enzyme, while fVaDEDE, and fVaDFDF gave values that were normal. The
data presented suggests that the

695

DY696 portion of the acidic cluster found in the

COOH-terminus of the fVa heavy chain plays a significant role in enzyme-substrate
interaction during thrombus formation.
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4.2 Introduction
The penultimate goal of the coagulation response is the generation of thrombin,
which in turn converts fibrinogen to fibrin to produce a fibrin plug. This cascade of
enzymatic reactions begins immediately after vascular injury and is a tightly regulated
process involving a multitude of proteins and enzyme complexes. The proteolytic
conversion of prothrombin to thrombin is catalyzed by the prothrombinase complex
composed of the enzyme, factor Xa, its cofactor, factor Va, assembled on a membrane
surface in the presence of divalent metal ions [6]. Although factor Xa can activate
prothrombin with an initial cleavage at Arg271 followed by cleavage at Arg320 to yield the
intermediates Fragment 1.2 and Prethrombin 2, incorporation of factor Va into the
prothrombinase complex results in a reversal of cleavages and a 300,000-fold increase in
the catalytic efficiency of factor Xa for thrombin generation [7]. A first cleavage of
prothrombin

by

prothrombinase

at

Arg320

produces

the

active

intermediate

meizothrombin (Fragment 1.2A), while the second cleavage at Arg271 produces thrombin.
The incorporation of factor Va into the prothrombinase complex is of absolute
importance to the production of thrombin during the coagulation response.

It exists in

the human body at a physiological concentration of 20nM and presents itself as a single
chain protein with a Mr of 330,000 [8]. The cofactor is composed of three protein
domains (A, B, & C) that are arranged in the order of A1-A2-B-A3-C1-C2. It is cleaved
by α-thrombin (fIIa) at Arg709, Arg1018, and Arg 1545 to release the B domain (containing a
large number of asparagine-linked oligosaccharides) and generate an active cofactor
(fVaIia) composed of a light chain of Mr 74 kDa (A3-C1-C2 domains) and a heavy chain
of Mr 105 kDa (A1-A2 domains) [9, 10]. It has been frequently demonstrated that factor
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Va will increase the efficiency of factor Xa by decreasing the Km by 100-fold and
increasing Kcat values by 3,000-fold [11]. This decrease in Km is due to tighter binding of
factor Xa to the membrane surface, allowing higher concentrations of the enzyme to
localize while the Kcat value is improved due to factor Va interaction with factor Xa [12].
Although the factor Va heavy chain interacts with factor Xa and anion exosite I of
prothrombin during its conversion to thrombin, the exact mechanism by which this
occurs has not been clarified [13]. Anion exosite I is known to be rich in basic amino
acid residues that may interact with the factor Va molecule [14]. The carboxy-terminal
region of the factor Va heavy chain contains small clusters of acidic amino acids, which
are believed to play a role in the cofactor effect of the molecule on the prothrombinase
complex [15]. We recently showed that amino acid region 680-709 of the heavy chain
regulates proteolytic cleavage of the substrate, prothrombin, at Arg

271

by decreasing the

rate of cleavage [3, 16]. In addition, a pentapeptide (DYDYQ) consisting of the region
Asp695-Gln699 was also found to inhibit prothrombinase function as well as inhibiting
activation of factor V by human alpha thrombin. The following studies were undertaken
to further understand the importance of the COOH-terminal region of the factor Va heavy
chain during proteolytic cleavage of prothrombin by prothrombinase.
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4.3 Experimental Procedures
Diisopropyl-fluorophosphate (DFP), O-

Materials reagents, and proteins.
phenylenediamine

–dihydrochloride

(OPD),

N-[2-Hydroxyethyl]piperazine-N'-2-

ethanesulfonic acid (Hepes), Trizma (Tris base), and Coomassie Blue R-250 were
purchased from Sigma (St. Louis, Mo). Factor V-deficient plasma was from Research
Proteins

Inc

(Essex

Junction

VT).

L-α-phosphatidylserine

(PS)

and

phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL).

L-a-

Normal

reference plasma and the chromogenic substrate H-D-Hexahydrotyrosol-alanyl-arginyl-pnitroanilide diacetate (Spectrozyme-TH) were purchased from American Diagnostica Inc.
(Greenwich,

CT).

H-D-Phenylalanyl-L-pipecolyl-L-arginyl-p-nitroaniline

dihydrochloride (Chromogenix, S-2238) was purchased from Diapharma Group, Inc.
(West Chester, OH) and its concentration in solution (water) was verified as described
(41).

RecombiPlasTin for the clotting assays was purchased from Instrumentation

Laboratory Company (Lexington, MA). The reversible fluorescent α-thrombin inhibitor
dansylarginine N,N-(3-ethyl-1,5-pentanediyl)amide (DAPA), human prothrombin, RVVV activator, and human α-thrombin, were from Haematologic Technologies Inc. (Essex
Junction, VT). Active-site blocked human meizothrombin (obtained following digestion
of prothrombin with the purified component from the venom of the snake Echis
Carinatus as described). FPR-meizothrombin was provided by Dr. Rick Jenny
(Haematologic Technologies Inc, Essex Junction VT).
Enzyme Research Laboratories (South Bend, IN).

Human factor Xa was from

Human cathepsin G was from

Calbiochem (EMD Chemicals, Inc. San Diego, CA). All molecular biology and tissue
culture reagents and media were from Gibco, Invitrogen Corporation (Grand Island, NY).
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Human plasma factor V was purified and concentrated using methodologies previously
described employing the monoclonal antibody αhFV#1 coupled to Sepharose. Digestion
of factor Va by a-thrombin and cathepsin G (to obtain factor VaII/CG) and/or the purified
enzyme from Naja Naja Nigricollis (factor VaNN) were performed as described. The
clotting activities of all factor Va preparations was measured by a clotting assay using
factor V deficient plasma and standardized to the percentage of control as described
using an automated coagulation analyzer (START-4, Diagnostica Stago, Parsippany, NJ).
Recombinant wild type prothrombin and prothrombin rMZ-II that has only one cleavage
site for factor Xa (i.e. Arg320) were prepared and purified as previously described
Phospholipid vesicles composed of 75% PC and 25% PS (referred to as PCPS vesicles
throughout the manuscript) were prepared as previously described.
Mutant factor V with the

Construction of Recombinant FV Molecules.
substitutions

695

DYDY698→DEDE

(factor

VDEDE)

was

constructed

using

the

QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA)
according to the manufacturer’s instructions with the following primers (underlined
nucleotides represent the mismatch): 5’-GAGAGTGATGCTGACGAAGATGAACAG
3’(sense) and 5’-CTGTTCATCTTCGTCAGCATCACTCTC-3’ (anti-sense).

The

deletion mutant (factor VDFDF)) was constructed with the same kit. Primers for factor
VDFDF

were

5’-GAGAGTGATGCTGACTTTGATTTCCAG-3’

CTGGAAATCAAAGTCAGCATCACTCTC-3’ (anti-sense).
factor

VKFDY

with

the

following

GAGAGTGATGCTAAGTTTGATTACCAG-3’

primers

(sense)

and

5’-

In addition, the mutant

was

(sense)

constructed:

5’-

and

5’-

CTGGTAATCAAACTTAGCATCACTCTC -3’ (antisense). One more mutant was also
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made, factor VDFDY with primers: 5’-GAGAGTGATGCTGACTTTGATTACCAG-3’
(sense) and 5’-CTGGTAATCAAAGTCAGCATCACTCTC-3’ (antisense).

PCR

products were transformed into competent E. Coli cells and positive ampicillin-resistant
clones were selected. Before transfection, all mutant constructs were verified following
sequencing in the Cleveland State University DNA Analysis Facility using a Beckman
Coulter CEQ 8000 Genetic Analysis System (Beckman, Fullerton CA) with factor-V
sequence-specific primers. The wild type pMT2-FV and mutant pMT2-FV plasmids
were isolated from the bacterial culture by the QIAfilter High Speed plasmid Midi Kit
(Qiagen Inc., Valencia, CA).
Expression of Recombinant Wild Type and Mutant Factor V in Mammalian
Cells. COS-7L and COS-7 cells (Invitrogen) were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, and
antibiotics (100 μg/ml streptomycin and 100 IU/ml penicillin) in a humidified
atmosphere of 5% CO2 and 95% air at 37°C. Purified factor VWt, factor VD680-709, and
factor V4A plasmids were transfected into the cells as described. Purification of all
recombinant factor V molecules was performed as described. The concentration of all
molecules was assessed by ELISA as detailed.

The activity and integrity of the

recombinant molecules was verified before and after activation with thrombin by clotting
assays using factor V-deficient plasma and and in several experiments by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting
using monoclonal and polyclonal antibodies.
Analysis of Prothrombin Activation and FPR-Meizothrombin Cleavage at Arg271
by Gel Electrophoresis.

Prothrombin (1.4μM) was incubated with PCPS vesicles
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(20μM), DAPA (50μM), and factor Va (10-30nM) in a buffer composed of 5 mM Ca2+ in
20 mM Tris, 0.15 M NaCl, pH 7.4. The reaction was initiated with the addition of factor
Xa (0.5-1nM) at room temperature over a 1 h time course. Aliquots (50 μl) from the
reaction were removed at selected time intervals (as indicated in the legend to the figures)
treated as described and analyzed using 9.5% SDS-PAGE.

Prothrombin and

prothrombin-derived fragments were visualized by Coomassie Blue staining. Scanning
densitometry and calculation of the rates of prothrombin consumption were performed as
described. FPR-meizothrombin cleavage at Arg271 was assessed in a similar manner.
Gel Electrophoresis and Western Blotting. SDS-PAGE analyses of recombinant
proteins following activation were performed using 5-15% gradient gels according to the
method of Laemmli. Proteins were transferred to polyvinylidene difluoride (PVDF)
membranes according to the method described by Towbin et al.

After transfer to

nitrocellulose, factor Va heavy and light chain(s) were detected using the appropriate
monoclonal and polyclonal antibodies. Immunoreactive fragments were visualized with
chemiluminescence.
Measurement of Rates of Thrombin Formation in a Prothrombinase Assay.
rMZ-II and recombinant prothrombin were activated by prothrombinase prior to the
experiment using conditions previously described.

Subsequent gel electrophoresis

analyses under reducing conditions were performed to verify that both rMZ-II and the
recombinant prothrombin preparations were activated to the same extent. The enzymes
(rMZ-IIa and recombinant a-thrombin) used for the titration of Spetrozyme-TH and S2238 were assayed at a constant concentration (4.3 nM), as previously described using
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serial dilutions of chromogenic substrate.

The absorbance was monitored with a

Thermomax microplate reader (Molecular Devices, Sunnyvale, CA).
Functionally defined apparent dissociation constants (KDapp) for factor Va binding to
factor Xa-PCPS were obtained from plots measuring the rate of thrombin generation as a
function of factor Va concentration in the presence of a limiting, (constant) concentration
of factor Xa. Throughout all experiments the assumption was n=moles of factor Xa
bound/mole of factor Va at saturation; throughout this study n=1; the stoichiometry of the
factor Va-factor Xa interaction was fixed at 1. The initial rate of the formation of
thrombin (initial velocity in nM⋅IIa⋅min-1) was calculated, and the data were analyzed and
plotted using the software Prizm (Graphpad Software Inc, San Diego CA) according to
the one binding site model. Dissociation constants were extracted directly from the
graphs.
The assay using purified reagents and verifying the activity of the recombinant factor
V molecules was conducted under conditions were all factor Xa was saturated with factor
Va, as described by measuring a-thrombin formation by the change in the absorbance of a
chromogenic substrate at 405 nm (Spectrozyme-TH, 0.4 mM). All factor V molecules
were activated with thrombin as describe. Knowing the (KDapp) of each factor Va species
for factor Xa, the amount necessary to saturate factor Xa was calculated using the
quadratic equation described in the literature before each experiment.

The total

concentration of ligand (VaT) used was modified as appropriate to obtain between 9598% saturation of the factor Xa molecule. The absorbance was monitored with a
Thermomax microplate reader and compared to an a-thrombin standard prepared daily
using purified plasma-derived a-thrombin. The data were analyzed and plotted using the
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software Prizm according to the Michaelis-Menten equation. Kinetic constants provided
throughout the manuscript were extracted directly from the graphs.
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4.4 Results
Expression of Recombinant Factor V Molecules and Activation. To analyze
the importance of amino acids 695 and 696 of the heavy chain of factor V, four
recombinant mutant molecules were synthesized using site-directed mutagenesis. Factor
VDEDE and factor VDFDF (DY696DY698→DEDE, DFDF) were constructed along with
factor V

KFDY

and factor VDFDY (D695FDY→KFDY, DFDY) (Fig. 4.1).

These

recombinant factor V molecules along with wild-type factor V were transiently expressed
in COS 7L cells and the recombinant proteins were harvested and purified.

The

concentration of the various proteins was determined by ELISA [11].
Western blot analysis was first done to determine the integrity of the recombinant
proteins using anti-factor V antibodies that recognize an epitope on the light (α-fV #9)
and heavy (α-fV #17) chains of the factor V molecule (Fig.4.2). All molecules were
activated with human α-thrombin and clotting activity was assessed in a two-stage
clotting assay (Table 4.1). Factor Vwild-type (fVWT) showed clotting activity that was
normal along with factor VDFDF (fVDFDF), factor VDFDY, and factor VDEDE (fVDEDE ). In
contrast, fVKFDY had clotting activity that was decreased and resulted in a prolonged
clotting time (30.3s)(Table 4.I). The results obtained indicate that the mutations at amino
acid residues D695Y696→KF have a profound effect on the cofactor.
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FVDEDE ,FVDFDF,FVDFDY,FVKFDY
680KMHDRLEPEDEESDADYDYQNRLAAALGIR709

NH2

B Domain

1

A1

A2

71,000

Arg709 Arg1018

(α‐IIa)

2196

150,000

(α‐IIa)
(RVV‐V)

A3

C1

C2

COOH

Arg1545

(α‐IIa)
(RVV‐V)

Figure 4.1. Factor V structure and mutant Molecules. The procofactor, factor
V, is composed of three A domains, a connecting B region, and two C domains. Factor
Va is generated following three sequential cleavages of factor V by α-thrombin at Arg709,
Arg1018, and Arg1545. The mutations within the acidic hirudin-like COOH-terminus
region of the heavy chain (amino acid residues 695-698) are indicated together with the
designation of the recombinant mutant factor V molecules created and used throughout
the manuscript.
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Figure 4.2. Electrophoretic analyses of wild type factor V and recombinant
factor V molecules. Factor VWt, factor VKFDY, factor VDFDY, factor VDFDF, and factor
VDEDE were activated with thrombin as described in the “Experimental Procedures”
section and analyzed by SDS-PAGE. Following transfer to a PVDF membrane,
immunoreactive fragments were detected with monoclonal antibodies αHFVaHC17
(recognizing an epitope on the heavy chain of the cofactor between amino acid residues
307-506) and αHFVaHC9 (recognizing the light chain). At the right the positions of the
heavy/light chains of factor Va are shown.
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Factor Va

Clotting Time(s)

FVaWT

14.0±2.02

FVaDEDE

19.8±0.39

FVaDFDF

14.4±0.43

FVaDFDY

13.6±1.11

FVaKFDY

30.3±4.60

Table 4.I. Clotting assay with factor VaWT and recombinant mutant
molecules. Two-stage clotting assays of recombinant factor V molecules was performed
as described in the “Experimental Procedures” section. As seen above, FVaDFDF, and
FVaDFDY, and FVaDEDE all had clotting times that were in the normal range as compared
to FVaWT, while FVaKFDY revealed a prolonged clotting time.
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Kinetic Analysis of Prothrombinase Assembled with Recombinant Factor Va
molecules.

The cofactor effect on prothrombin activation when assembled in the

prothrombinase complex has been a topic of heated discussion for the past decade. It has
been repeatedly shown by our lab that the factor Va carboxy-terminal region of the heavy
chain contains acidic amino acid residues that are important for interaction of
prothrombinase with its substrate, prothrombin [16, 3]. The exact mechanism of how this
takes place is still not known. To establish what specific effects the residues at 695 and
696 of the heavy chain have on prothrombinase activity, the following kinetic assays
were performed.
Factor Va titrations were performed using a limiting amount of factor Xa (15 pM)
to assess the ability of the factor Va mutants to bind factor Xa (fXa) during
prothrombinase complex formation. Varying concentrations of fVa were titrated in a
mixture consisting of all components of the prothrombinase complex and the substate,
prothrombin.

Thrombin generation was measured by cleavage of a chromogenic

substrate. The data obtained demonstrates that fVaWT has an affinity for fXa that is the
same as plasma-derived fVa. In analyzing results for fVaDEDE, fVaDFDF, fVaDFDY, and
fVaKFDY, it was discovered that all of these mutant fVa molecules also have the same
affinity for fXa as wild-type with Kd values that were less than 1.0 nM (Fig. 4.3). These
results indicate that mutation of these critical amino acids does not have any effect on
fVa-fXa binding.
To further evaluate the effect of the mutations on the heavy chain of the fVa
molecules, prothrombin titrations were performed to determine Kcat and Km values. A
limiting concentration of fXa (10 pM) was combined with 20 nM fVa in the presence of
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varying amounts of prothrombin (25nM-4uM). Experiments done with fVaWT showed
that the catalytic efficiency of prothrombinase during proteolytic cleavage of prothrombin
was normal when compared to values obtained with plasma fVa. Titrations done with
prothrombinase assembled with fVaDEDE, and fVaDFDF resulted in catalytic efficiencies
that were normal when compared to wild-type values. In contrast, studies performed
with fVaKFDY and fVaDFDY revealed a catalytic efficiency that was increased by 15% and
10%, respectively, when compared to fVaWT (Fig. 4.4). Meizothrombin, one of the
intermediates during prothrombin activation, has been found to cleave the substrate,
Spectrozyme-TH, at a higher rate than thrombin. Accumulation of this intermediate
caused by fVaKFDY , leads to the increase in Kcat (2355 min-1) value that was observed.
Analysis of Prothrombin Activation by Prothrombinase Assembled with
FVaWT, FVaDEDE, FVaDFDF, FVaDFDY, and FVaKFDY. To visualize the activation of
prothrombin by prothrombinase, assembled with the various recombinant factor V
molecules, analysis by SDS-PAGE was done. Each cofactor molecule was included in a
mixture consisting of 1.4 uM prothrombin, a membrane surface (20 uM PC/PS), and
calcium. Factor Xa was added to start the reaction and 50 ul samples were pulled at time
points over a 1 hour time course. Results show that prothrombin activation occurred
through the meizothrombin pathway for all of the recombinant fVa molecules (Fig. 4.5).
This pathway is characterized by initial cleavage of prothrombin at Arg320 to reveal
fragment 1.2A, also known as meizothrombin. Gel analysis showed that proteolytic
cleavage of prothrombin by prothrombinase assembled with fVaWT, fVaDEDE, and
fVaDFDF occured in a timely fashion and was normal. On the other hand, prothrombinase
consisting of fVaKFDY and fVaDFDY resulted in accumulation of meizothrombin,
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represented by fragment 1.2A, with fVaKFDY showing a more prominent effect and
fVaDFDY showing slight accumulation. These results lead to the conclusion that fVaKFDY
leads to impairment of proteolytic processing of the prothrombin molecule.
Analysis of Prothrombin Cleavage Rates by the Prothrombinase Assembled
with Recombinant Mutant FVa Molecules. To understand the effect of the mutations
at amino acids 695-698 of the factor Va heavy chain on cleavage at Arg271 of
prothrombin, FPR-meizothrombin activation was done by prothrombinase assembled
with fVaWT and the recombinant mutant fVa molecules. Experimental analysis of FPRmeizothrombin cleaved with prothrombinase assembled with fVaWT, fVaDEDE, and
fVaDFDF ,all revealed no effect on cleavage at Arg271, while the rate of cleavage by
prothrombinase assembled with fVaKFDY and fVaDFDY was delayed as displayed in figure
4.6. The prolonged presence of fragment 1.2A during the reaction with fVaKFDY points to
695

DY696 of the factor Va heavy chain has a regulating effect on proteolytic

the fact that

processing of the prothrombin intermediate at the Arg271 cleavage site, leading to a delay
in thrombin formation. From the data obtained through this assay, we can therefore
conclude that mutation of amino acid residues 695 and 696 of the COOH-terminal region
of the factor Va heavy chain has a negative effect on the proteolytic conversion of
meizothrombin to human α-thrombin. In addition, it can also be assumed that the
sequence

695

DY696 plays an important role in factor Va regulation of prothrombinase

function towards the activation of prothrombin.
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Figure 4.3. Factor Va titrations to determine the affinity of the recombinant
factor Va molecules for factor Xa. Thrombin generation experiments were carried out
as described under “Experimental Procedures”. Prothrombinase complex was assembled
with varying concentrations of recombinant factor VaWT (filled squares), factor VaDFDY
(filled triangles), factor VaKFDY (filled inverse triangles), factor VaDEDE(filled diamonds),
and fVaDFDF(filled circles). The dissociation constants (Kd) were obtained using the
GraphPad Prism software.
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Figure 4.4. Prothrombin titration to determine the kinetic parameters of
prothrombinase assembled with various recombinant factor Va species. Thrombin
generation experiments were carried out as described under “Experimental Procedures”
by varying the substrate concentration (25 nM to 4 µM) with 10 pM of factor Xa
saturated with the factor Va species. Prothrombinase complex was assembled with
recombinant factor VaWT (filled squares), factor VaKFDY (filled triangles), factor VaDFDY
(filled inverse triangles), factor VaDEDE(filled diamonds), and fVaDFDF(filled circles). The
solid lines represent a nonlinear regression fit of the data using Prizm GraphPad software
for a one binding site model.
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Figure 4.5. Analysis of the activation of plasma-derived prothrombin by
prothrombinase. Plasma-derived prothrombin (1.4 μM) was incubated in different
mixtures with PCPS vesicles (20 μM), and prothrombinase assembled with either factor
VaWT , factor VaKFDY , factor VaDFDY, factor VaDEDE, and factor VaDFDF as described in
the “Experimental Procedures” section.
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Figure 4.6. Gel electrophoresis analyses for cleavage of FPR-meizothrombin.
FPR-meizothrombin (1.4 μM) was incubated in different mixtures with PCPS vesicles
(20 μM) and factor Va (20 nM). The reactions were started by the addition of factor Xa
and the samples were further treated, scanned and quantified as detailed in the
“Experimental Procedures” section.
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4.5 Discussion
In retrospect, our data has demonstrated that the amino acids

695

DY696 of the

factor Va heavy chain play a significant role in prothrombinase activation of its substrate,
prothrombin.

Through experimental analysis using kinetic studies and recombinant

proteins, we have shown that this portion of the carboxy-terminal region of the heavy
chain induces a delay in cleavage at Arg271 during prothrombin activation. This sequence
on the factor V molecule has been found to be highly conserved amongst various species
including bovine, chimp, and mouse sequences, pointing out the significance of the
region.
There have been conflicting reports by other laboratories stating that the carboxyterminus of the factor Va heavy chain has no major impact on prothrombinase function
[17]. In our lab, we have demonstrated that the COOH-terminal region of the factor Va
heavy chain plays an important part on the complex’s function and regulates the amount
of meizothrombin that lingers during prothrombin activation through delayed cleavage at
Arg271. In these studies, we determined that it is specifically amino acid residues 695 and
696 who are responsible for timely cleavage of the substrate by the prothombinase
complex. In order for prothrombinase to properly align itself with prothrombin to have
efficient cleavage, these two amino acids must be in presence.
Kinetic analysis through fVa titration assays were done to determine the effects of
695

DY696, did not

affect the affinity of fVa to fXa when Kd values were determined.

In addition,

mutations done to the fVa heavy chain. Mutation of the sequence,

prothrombin titration assays using varying concentrations of the substrate with all
components of the prothrombinase complex resulted in Kcat values that were normal for
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all recombinant mutants constructed except for fVaKFDY and fVaDFDY. In the case of
prothrombinase assembled with fVaKFDY and fVaDFDY, the catalytic efficiency of the
enzyme complex was actually increased when thrombin generation was measured using a
chromogenic substrate. This can be explained due to the fact that these mutations cause
the accumulation of the intermediate, meizothrombin during prothrombin activation. It
has bee previously determined that meizothrombin cleaves the chromogenic substrate,
spectrozyme-TH, more efficiently than thrombin, leading to a higher Kcat value.
As an overall conclusion, we have determined that the acidic cluster of amino acids,
DYDYQ, at the carboxy-terminus of the factor Va heavy chain play a crucial role in
thrombin generation by the prothrombinase complex and that this effect can be
specifically attributed to the combined effects of amino acid residues 695 and 696.
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CHAPTER V
OVERALL CONCLUSION

5.1 Conclusion
Heart disease is presently one of the leading causes of death around the world.
Individuals treated with medications to relieve cardiovascular complications are exposed
to various side effects. Thrombin inhibitors are one type of drug that targets serine
proteases, which are involved in the blood coagulation. Although these inhibitors aid
patients with their ailments, they are non-specific and cause complications such as,
excessive bleeding after injury. To develop new treatments for the numerous ailments
associated with cardiovascular problems, a deeper understanding of the molecular
mechanisms involved in the blood coagulation response must be obtained.
The ultimate goal of the coagulation cascade is to form a fibrin clot that is
catalyzd by the serine protease, human α-thrombin. The prothrombinase complex plays a
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crucial role in the formation of thrombin.

The efficiency of factor Xa to cleave

prothrombin is increased considerably by the inclusion of its cofactor, factor Va. We
have repeatedly confirmed in our lab, that factor Va serves to regulate prothrombinase
function during hemostasis and may be the key to the development of a better anticoagulant drug.
There are two different pathways by which prothrombin activation can occur.
Pathway I involves factor Xa alone that will cleave prothrombin initially at Arg271
followed by cleavage at Arg320 to reveal thrombin. Pathway II involves the incorporation
of factor Va and results in a reversal of cleavages with initial cleavage of prothrombin ar
Arg320

[1].

This pathway is characterized by formation of an intermediate,

meizothrombin that has been shown to have catalytic properties and increases factor Xa
efficiency towards prothrombin activation. Our lab has recently established that the
factor Va heavy chain contains a specific cluster of amino acids on the COOH-terminal
end that interact with prothrombin/thrombin [2]. In addition, we also analyzed a peptide
with the sequence 695DYDYQ699 that was shown to competitively inhibit prothrombinase
function by competing for a binding site on prothrombin [3].

It has also been

demonstrated that prothrombinase assembled with a factor Va molecule that was cleaved
with cathepsin G or human neutrophil elastase lead to a truncated molecule at the COOH
end that lead to a higher Kcat value and poor clotting activity [4]. We synthesized a
recombinant mutant fV molecule to determine the extent of the effects of this region.
The deletion of amino acids 680-709 resulted in a recombinant protein that increased the
catalytic efficiency of factor Xa in regards to proteolytic processing of prothrombin.
These results were due to the accumulation of meizothrombin when prothrombinase was
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assembled with the deletion mutant, fVa680-709.

The prolonged appearance of this

intermediate was found to be due to a reduced rate of cleavage at Arg271. These results
pointed to the importance of the factor Va heavy chain for prothrombinase function.
In addtion to 695DYDYQ699, our lab also investigated amino acids 334-335 which
also consist of the DY motif. Mutations to these two residues resulted in impaired
clotting activity and a reduced Kcat value for prothrombinase assembled with these
recombinant fVa mutants.

[5]. To further investigate the important role that acidic

amino acids of factor Va play during coagulation, we constructed recombinant mutants
within amino acids 659-663. A deletion mutant (fVa659-664) along with point mutations
(fVa5K) were tested within prothrombinase to evaluate kinetic values and rates of
cleavage of the substrate, prothrombin. Results displayed that mutations to this small
portion of the fVa heavy chain lead to a reduced rate of cleavage of prothrombin at both,
Arg320 and Arg271. In addition, the Kcat values for prothrombinase formed with these
mutants were reduced and clotting times were impaired. Overall, these experiments point
to the important role that acidic amino acids play in the formation of thrombin.
To elucidate the effects of amino acid residues 695-698 on cofactor function
during prothrombin activation and to determine which specidic amino acids in this
sequence were responsible for optimal cofactor function, we created fV mutants VaDEDE,
fVaDFDF, fVaDFDY, and VaKFDY. From studies performed in our lab, we determined that
695

DY696 of this sequence were required for proper thrombin formation. FVaKFDY was

found to give prothrombinase an increased Kcat value, but resulted in impaired clotting
activity due to the accumulation of the intermediate, meizothrombin. All of the other
recombinant mutants were normal when compared to fVaWT. Tyrosine sulfation is an
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important modification that occurs to the factor V molecule. It is essential for proper
cofactor activation and function. Tyr696 , Tyr698, and Tyr1510 have been identified as
potential sulfo-tyrosine sites of factor V [6].

Results obtained in our studies with

fVaKFDY, indicate that Tyr696 of the factor Va heavy chain plays an important role in
coafactor regulation of the prothrombinase complex.
Heart disease and stroke have enormous effects on the world population on hand.
It is of great importance to initiate a method of therapy that will cut the number of current
cases as well as ones that will develop in the future. In order to do this, it is necessary to
further investigate the effects of the coagulation cascade and its numerous members. In
particular, the cofactor, factor Va and its involvement in clot formation.
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